[
  {
    "id": "doc:fda.verzenio",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Verzenio (abemaciclib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 208716,
    "company": "Eli and Lily Company.",
    "drug_name_brand": "Verzenio",
    "drug_name_generic": "abemaciclib",
    "first_publication_date": null,
    "publication_date": "2023-03-03",
    "status": "Active"
  },
  {
    "id": "doc:fda.akeega",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Akeega (abiraterone acetate and niraparib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Janssen Biotech, Inc. Akeega (abiraterone acetate and niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216793s001lbl.pdf. Revised December 2025. Accessed February 5, 2026.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216793s001lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216793"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 216793,
    "company": "Janssen Biotech, Inc.",
    "drug_name_brand": "Akeega",
    "drug_name_generic": "abiraterone acetate and niraparib",
    "first_publication_date": null,
    "publication_date": "2025-12-12",
    "status": "Active"
  },
  {
    "id": "doc:fda.krazati",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Krazati (adagrasib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Mirati Therapeutics, Inc. Krazati (adagrasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf. Revised December 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216340"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 216340,
    "company": "Mirati Therapeutics, Inc.",
    "drug_name_brand": "Krazati",
    "drug_name_generic": "adagrasib",
    "first_publication_date": "2022-12-12",
    "publication_date": "2022-12-12",
    "status": "Active"
  },
  {
    "id": "doc:fda.kadcyla",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Kadcyla (ado-trastuzumab emtansine) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf. Revised January 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 125427,
    "company": "Genentech, Inc.",
    "drug_name_brand": "Kadcyla",
    "drug_name_generic": "ado-trastuzumab emtansine",
    "first_publication_date": null,
    "publication_date": "2022-02-02",
    "status": "Active"
  },
  {
    "id": "doc:fda.gilotrif",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Gilotrif (afatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf. Revised April 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201292"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 201292,
    "company": "Boehringer Ingelheim Pharmaceuticals, Inc.",
    "drug_name_brand": "Gilotrif",
    "drug_name_generic": "afatinib",
    "first_publication_date": null,
    "publication_date": "2022-04-07",
    "status": "Active"
  },
  {
    "id": "doc:fda.alecensa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Alecensa (alectinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf. Revised February 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208434"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 208434,
    "company": "Genentech, Inc.",
    "drug_name_brand": "Alecensa",
    "drug_name_generic": "alectinib",
    "first_publication_date": "2015-12-11",
    "publication_date": "2024-04-18",
    "status": "Active"
  },
  {
    "id": "doc:fda.piqray",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Piqray (alpelisib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 212526,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Piqray",
    "drug_name_generic": "alpelisib",
    "first_publication_date": null,
    "publication_date": "2024-01-18",
    "status": "Active"
  },
  {
    "id": "doc:fda.rybrevant",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rybrevant (amivantamab-vmjw) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761210,
    "company": "Janssen Biotech, Inc.",
    "drug_name_brand": "Rybrevant",
    "drug_name_generic": "amivantamab-vmjw",
    "first_publication_date": "2021-05-21",
    "publication_date": "2024-09-19",
    "status": "Active"
  },
  {
    "id": "doc:fda.trisenox",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trisenox (arsenic trioxide) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf. Revised October 2020. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 21248,
    "company": "Cephalon, Inc.",
    "drug_name_brand": "Trisenox",
    "drug_name_generic": "arsenic trioxide",
    "first_publication_date": null,
    "publication_date": "2020-10-20",
    "status": "Active"
  },
  {
    "id": "doc:fda.scemblix",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Scemblix (asciminib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed January 10, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 215358,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Scemblix",
    "drug_name_generic": "asciminib",
    "first_publication_date": null,
    "publication_date": "2024-10-29",
    "status": "Active"
  },
  {
    "id": "doc:fda.tecentriq",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tecentriq (atezolizumab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761034,
    "company": "Genentech, Inc.",
    "drug_name_brand": "Tecentriq",
    "drug_name_generic": "atezolizumab",
    "first_publication_date": null,
    "publication_date": "2024-04-22",
    "status": "Active"
  },
  {
    "id": "doc:fda.ayvakit",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ayvakit (avapritinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf. Revised May 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212608"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 212608,
    "company": "Blueprint Medicines Corporation.",
    "drug_name_brand": "Ayvakit",
    "drug_name_generic": "avapritinib",
    "first_publication_date": null,
    "publication_date": "2023-05-22",
    "status": "Active"
  },
  {
    "id": "doc:fda.mektovi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Mektovi (binimetinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Array BioPharma, Inc. Mektovi (binimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf. Revised October 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210498"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 210498,
    "company": "Array BioPharma, Inc.",
    "drug_name_brand": "Mektovi",
    "drug_name_generic": "binimetinib",
    "first_publication_date": null,
    "publication_date": "2023-10-11",
    "status": "Active"
  },
  {
    "id": "doc:fda.blincyto",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Blincyto (blinatumomab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Amgen, Inc. Blincyto (blinatumomab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf. Revised June 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 125557,
    "company": "Amgen, Inc.",
    "drug_name_brand": "Blincyto",
    "drug_name_generic": "blinatumomab",
    "first_publication_date": "2024-12-03",
    "publication_date": "2024-06-14",
    "status": "Active"
  },
  {
    "id": "doc:fda.bosulif",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Bosulif (bosutinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer, Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203341"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 203341,
    "company": "Pfizer, Inc.",
    "drug_name_brand": "Bosulif",
    "drug_name_generic": "bosutinib",
    "first_publication_date": null,
    "publication_date": "2023-09-26",
    "status": "Active"
  },
  {
    "id": "doc:fda.adcetris",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Adcetris (brentuximab vedotin) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Seagen Inc. Adcetris (brentuximab vedotin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf. Revised June 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 125388,
    "company": "Seagen Inc.",
    "drug_name_brand": "Adcetris",
    "drug_name_generic": "brentuximab vedotin",
    "first_publication_date": null,
    "publication_date": "2023-06-14",
    "status": "Active"
  },
  {
    "id": "doc:fda.alunbrig",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Alunbrig (brigatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Takeda Pharmaceuticals America, Inc. Alunbrig (brigatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf. Revised February 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208772"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 208772,
    "company": "Takeda Pharmaceuticals America, Inc.",
    "drug_name_brand": "Alunbrig",
    "drug_name_generic": "brigatinib",
    "first_publication_date": null,
    "publication_date": "2022-02-28",
    "status": "Active"
  },
  {
    "id": "doc:fda.xeloda",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Xeloda (capecitabine) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech, Inc. Xeloda (capecitabine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf. Revised December 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020896"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 20896,
    "company": "Genentech, Inc.",
    "drug_name_brand": "Xeloda",
    "drug_name_generic": "capecitabine",
    "first_publication_date": null,
    "publication_date": "2022-12-14",
    "status": "Active"
  },
  {
    "id": "doc:fda.truqap",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Truqap (capivasertib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 218197,
    "company": "AstraZeneca Pharmaceuticals, LP.",
    "drug_name_brand": "Truqap",
    "drug_name_generic": "capivasertib",
    "first_publication_date": "2023-11-16",
    "publication_date": "2023-11-16",
    "status": "Active"
  },
  {
    "id": "doc:fda.tabrecta",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tabrecta (capmatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf. Revised March 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213591"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 213591,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Tabrecta",
    "drug_name_generic": "capmatinib",
    "first_publication_date": null,
    "publication_date": "2024-03-14",
    "status": "Active"
  },
  {
    "id": "doc:fda.libtayo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Libtayo (cemiplimab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Regeneron Pharmaceuticals, Inc. Libtayo (cemiplimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf. Revised April 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761097,
    "company": "Regeneron Pharmaceuticals, Inc.",
    "drug_name_brand": "Libtayo",
    "drug_name_generic": "cemiplimab",
    "first_publication_date": null,
    "publication_date": "2024-04-05",
    "status": "Active"
  },
  {
    "id": "doc:fda.zykadia",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Zykadia (ceritinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf. Revised October 2021. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211225"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 211225,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Zykadia",
    "drug_name_generic": "ceritinib",
    "first_publication_date": null,
    "publication_date": "2021-10-07",
    "status": "Active"
  },
  {
    "id": "doc:fda.erbitux",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Erbitux (cetuximab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "ImClone LLC. Erbitux (cetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf. Revised September 2021. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 125084,
    "company": "ImClone LLC.",
    "drug_name_brand": "Erbitux",
    "drug_name_generic": "cetuximab",
    "first_publication_date": null,
    "publication_date": "2021-09-24",
    "status": "Active"
  },
  {
    "id": "doc:fda.cotellic",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Cotellic (cobimetinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech USA, Inc. Cotellic (cobimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf. Revised May 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206192"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 206192,
    "company": "Genentech USA, Inc.",
    "drug_name_brand": "Cotellic",
    "drug_name_generic": "cobimetinib",
    "first_publication_date": null,
    "publication_date": "2023-05-31",
    "status": "Active"
  },
  {
    "id": "doc:fda.xalkori",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Xalkori (crizotinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf. Revised September 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 202570,
    "company": "Pfizer, Inc.",
    "drug_name_brand": "Xalkori",
    "drug_name_generic": "crizotinib",
    "first_publication_date": null,
    "publication_date": "2023-09-07",
    "status": "Active"
  },
  {
    "id": "doc:fda.tafinlar",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tafinlar (dabrafenib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 202806,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Tafinlar",
    "drug_name_generic": "dabrafenib",
    "first_publication_date": null,
    "publication_date": "2024-03-29",
    "status": "Active"
  },
  {
    "id": "doc:fda.vizimpro",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vizimpro (dacomitinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer, Inc. Vizimpro (dacomitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf. Revised December 2020. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211288"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 211288,
    "company": "Pfizer, Inc.",
    "drug_name_brand": "Vizimpro",
    "drug_name_generic": "dacomitinib",
    "first_publication_date": null,
    "publication_date": "2020-12-18",
    "status": "Active"
  },
  {
    "id": "doc:fda.sprycel",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Sprycel (dasatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 21986,
    "company": "Bristol-Myers Squibb Company.",
    "drug_name_brand": "Sprycel",
    "drug_name_generic": "dasatinib",
    "first_publication_date": null,
    "publication_date": "2023-02-08",
    "status": "Active"
  },
  {
    "id": "doc:fda.jemperli",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Jemperli (dostarlimab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "GlaxoSmithKline LLC. Jemperli (dostarlimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf. Revised March 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761174,
    "company": "GlaxoSmithKline LLC.",
    "drug_name_brand": "Jemperli",
    "drug_name_generic": "dostarlimab",
    "first_publication_date": null,
    "publication_date": "2024-03-06",
    "status": "Active"
  },
  {
    "id": "doc:fda.imfinzi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Imfinzi (durvalumab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761069,
    "company": "AstraZeneca UK Limited.",
    "drug_name_brand": "Imfinzi",
    "drug_name_generic": "durvalumab",
    "first_publication_date": "2017-05-01",
    "publication_date": "2024-08-15",
    "status": "Active"
  },
  {
    "id": "doc:fda.orserdu",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Orserdu (elacestrant) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Stemline Therapeutics, Inc. Orserdu (elacestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf. Revised May 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217639"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 217639,
    "company": "Stemline Therapeutics, Inc.",
    "drug_name_brand": "Orserdu",
    "drug_name_generic": "elacestrant",
    "first_publication_date": null,
    "publication_date": "2023-11-09",
    "status": "Active"
  },
  {
    "id": "doc:fda.idhifa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Idhifa (enasidenib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 209606,
    "company": "Celgene Corporation.",
    "drug_name_brand": "Idhifa",
    "drug_name_generic": "enasidenib",
    "first_publication_date": null,
    "publication_date": "2023-12-21",
    "status": "Active"
  },
  {
    "id": "doc:fda.braftovi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Braftovi (encorafenib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Array BioPharma, Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed January 10, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 210496,
    "company": "Array BioPharma, Inc.",
    "drug_name_brand": "Braftovi",
    "drug_name_generic": "encorafenib",
    "first_publication_date": "2018-06-27",
    "publication_date": "2024-12-20",
    "status": "Active"
  },
  {
    "id": "doc:fda.rozlytrek",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rozlytrek (entrectinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf. Revised January 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 212725,
    "company": "Genentech, Inc.",
    "drug_name_brand": "Rozlytrek",
    "drug_name_generic": "entrectinib",
    "first_publication_date": null,
    "publication_date": "2024-01-26",
    "status": "Active"
  },
  {
    "id": "doc:fda.balversa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Balversa (erdafitinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 212018,
    "company": "Janssen Products, LP.",
    "drug_name_brand": "Balversa",
    "drug_name_generic": "erdafitinib",
    "first_publication_date": null,
    "publication_date": "2024-01-19",
    "status": "Active"
  },
  {
    "id": "doc:fda.tarceva",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tarceva (erlotinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "OSI Pharmaceuticals, LLC. Tarceva (erlotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf. Revised October 2016. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021743"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 21743,
    "company": "OSI Pharmaceuticals, LLC.",
    "drug_name_brand": "Tarceva",
    "drug_name_generic": "erlotinib",
    "first_publication_date": null,
    "publication_date": "2016-10-18",
    "status": "Active"
  },
  {
    "id": "doc:fda.afinitor",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Afinitor (everolimus) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 22334,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Afinitor",
    "drug_name_generic": "everolimus",
    "first_publication_date": null,
    "publication_date": "2022-02-01",
    "status": "Active"
  },
  {
    "id": "doc:fda.faslodex",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Faslodex (fulvestrant) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 21344,
    "company": "AstraZeneca UK Limited.",
    "drug_name_brand": "Faslodex",
    "drug_name_generic": "fulvestrant",
    "first_publication_date": null,
    "publication_date": "2021-01-19",
    "status": "Active"
  },
  {
    "id": "doc:fda.lytgobi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lytgobi (futibatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214801s002lbl.pdf. Revised April 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214801s002lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214801"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 214801,
    "company": "Taiho Pharmaceutical Co., Ltd.",
    "drug_name_brand": "Lytgobi",
    "drug_name_generic": "futibatinib",
    "first_publication_date": null,
    "publication_date": "2024-04-17",
    "status": "Active"
  },
  {
    "id": "doc:fda.iressa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Iressa (gefitinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca Pharmaceuticals, LP. Iressa (gefitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf. Revised May 2021. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 206995,
    "company": "AstraZeneca Pharmaceuticals, LP.",
    "drug_name_brand": "Iressa",
    "drug_name_generic": "gefitinib",
    "first_publication_date": null,
    "publication_date": "2021-05-05",
    "status": "Active"
  },
  {
    "id": "doc:fda.mylotarg",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Mylotarg (gemtuzumab ozogamicin) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Wyeth Pharmaceuticals LLC. Mylotarg (gemtuzumab ozogamicin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf. Revised June 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761060,
    "company": "Wyeth Pharmaceuticals LLC.",
    "drug_name_brand": "Mylotarg",
    "drug_name_generic": "gemtuzumab ozogamicin",
    "first_publication_date": null,
    "publication_date": "2020-06-16",
    "status": "Active"
  },
  {
    "id": "doc:fda.xospata",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Xospata (gilteritinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 211349,
    "company": "Astellas Pharma US, Inc.",
    "drug_name_brand": "Xospata",
    "drug_name_generic": "gilteritinib",
    "first_publication_date": null,
    "publication_date": "2022-01-12",
    "status": "Active"
  },
  {
    "id": "doc:fda.gleevec",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Gleevec (imatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 21588,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Gleevec",
    "drug_name_generic": "imatinib",
    "first_publication_date": null,
    "publication_date": "2024-03-01",
    "status": "Active"
  },
  {
    "id": "doc:fda.truseltiq",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Truseltiq (infigratinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "QED Therapeutics, Inc. Truseltiq (infigratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214622"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 214622,
    "company": "QED Therapeutics, Inc.",
    "drug_name_brand": "Truseltiq",
    "drug_name_generic": "infigratinib",
    "first_publication_date": null,
    "publication_date": "2021-05-28",
    "status": "Active"
  },
  {
    "id": "doc:fda.besponsa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Besponsa (inotuzumab ozogamicin) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Wyeth Pharmaceuticals LLC. Besponsa (inotuzumab ozogamicin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761040"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761040,
    "company": "Wyeth Pharmaceuticals LLC.",
    "drug_name_brand": "Besponsa",
    "drug_name_generic": "inotuzumab ozogamicin",
    "first_publication_date": "2017-08-17",
    "publication_date": "2024-03-06",
    "status": "Active"
  },
  {
    "id": "doc:fda.yervoy",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Yervoy (ipilimumab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 125377,
    "company": "Bristol-Myers Squibb Company.",
    "drug_name_brand": "Yervoy",
    "drug_name_generic": "ipilimumab",
    "first_publication_date": "2011-03-25",
    "publication_date": "2025-04-11",
    "status": "Active"
  },
  {
    "id": "doc:fda.tibsovo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tibsovo (ivosidenib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 211192,
    "company": "Agios Pharmaceuticals, Inc.",
    "drug_name_brand": "Tibsovo",
    "drug_name_generic": "ivosidenib",
    "first_publication_date": null,
    "publication_date": "2023-10-24",
    "status": "Active"
  },
  {
    "id": "doc:fda.tykerb",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tykerb (lapatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf. Revised March 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 22059,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Tykerb",
    "drug_name_generic": "lapatinib",
    "first_publication_date": null,
    "publication_date": "2022-03-27",
    "status": "Active"
  },
  {
    "id": "doc:fda.vitrakvi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vitrakvi (larotrectinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf. Revised April 2025. Accessed April 30, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 210861,
    "company": "Loxo Oncology, Inc.",
    "drug_name_brand": "Vitrakvi",
    "drug_name_generic": "larotrectinib",
    "first_publication_date": "2018-11-26",
    "publication_date": "2025-04-09",
    "status": "Active"
  },
  {
    "id": "doc:fda.revlimid",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Revlimid (lenalidomide) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Company. Revlimid (lenalidomide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021880s067lbl.pdf. Revised March 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021880s067lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021880"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 21880,
    "company": "Bristol-Myers Squibb Company.",
    "drug_name_brand": "Revlimid",
    "drug_name_generic": "lenalidomide",
    "first_publication_date": null,
    "publication_date": "2023-03-24",
    "status": "Active"
  },
  {
    "id": "doc:fda.lorbrena",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lorbrena (lorlatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf. Revised March 2021. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210868"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 210868,
    "company": "Pfizer, Inc.",
    "drug_name_brand": "Lorbrena",
    "drug_name_generic": "lorlatinib",
    "first_publication_date": null,
    "publication_date": "2021-03-03",
    "status": "Active"
  },
  {
    "id": "doc:fda.margenza",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Margenza (margetuximab-cmkb) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "MacroGenics, Inc. Margenza (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf. Revised May 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761150"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761150,
    "company": "MacroGenics, Inc.",
    "drug_name_brand": "Margenza",
    "drug_name_generic": "margetuximab-cmkb",
    "first_publication_date": null,
    "publication_date": "2023-05-25",
    "status": "Active"
  },
  {
    "id": "doc:fda.rydapt",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rydapt (midostaurin) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 207997,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Rydapt",
    "drug_name_generic": "midostaurin",
    "first_publication_date": null,
    "publication_date": "2023-05-22",
    "status": "Active"
  },
  {
    "id": "doc:fda.exkivity",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Exkivity (mobocertinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Takeda Pharmaceuticals America, Inc. Exkivity (mobocertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf. Revised September 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 215310,
    "company": "Takeda Pharmaceuticals America, Inc.",
    "drug_name_brand": "Exkivity",
    "drug_name_generic": "mobocertinib",
    "first_publication_date": null,
    "publication_date": "2023-09-15",
    "status": "Active"
  },
  {
    "id": "doc:fda.nerlynx",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nerlynx (neratinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 208051,
    "company": "Puma Biotechnology, Inc.",
    "drug_name_brand": "Nerlynx",
    "drug_name_generic": "neratinib",
    "first_publication_date": null,
    "publication_date": "2021-06-28",
    "status": "Active"
  },
  {
    "id": "doc:fda.tasigna",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tasigna (nilotinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 22068,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Tasigna",
    "drug_name_generic": "nilotinib",
    "first_publication_date": null,
    "publication_date": "2024-02-29",
    "status": "Active"
  },
  {
    "id": "doc:fda.zejula",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Zejula (niraparib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 214876,
    "company": "GlaxoSmithKline.",
    "drug_name_brand": "Zejula",
    "drug_name_generic": "niraparib",
    "first_publication_date": null,
    "publication_date": "2023-04-26",
    "status": "Active"
  },
  {
    "id": "doc:fda.opdivo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Opdivo (nivolumab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 125554,
    "company": "Bristol-Myers Squibb Company.",
    "drug_name_brand": "Opdivo",
    "drug_name_generic": "nivolumab",
    "first_publication_date": "2014-12-22",
    "publication_date": "2025-04-11",
    "status": "Active"
  },
  {
    "id": "doc:fda.lynparza",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lynparza (olaparib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 208558,
    "company": "AstraZeneca Pharmaceuticals, LP.",
    "drug_name_brand": "Lynparza",
    "drug_name_generic": "olaparib",
    "first_publication_date": null,
    "publication_date": "2023-11-06",
    "status": "Active"
  },
  {
    "id": "doc:fda.rezlidhia",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rezlidhia (olutasidenib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215814"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 215814,
    "company": "Metrics Contract Services.",
    "drug_name_brand": "Rezlidhia",
    "drug_name_generic": "olutasidenib",
    "first_publication_date": null,
    "publication_date": "2022-12-01",
    "status": "Active"
  },
  {
    "id": "doc:fda.tagrisso",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tagrisso (osimertinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 208065,
    "company": "AstraZeneca Pharmaceuticals, LP.",
    "drug_name_brand": "Tagrisso",
    "drug_name_generic": "osimertinib",
    "first_publication_date": "2015-11-13",
    "publication_date": "2024-09-25",
    "status": "Active"
  },
  {
    "id": "doc:fda.ibrance",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ibrance (palbociclib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 207103,
    "company": "Pfizer, Inc.",
    "drug_name_brand": "Ibrance",
    "drug_name_generic": "palbociclib",
    "first_publication_date": null,
    "publication_date": "2023-09-06",
    "status": "Active"
  },
  {
    "id": "doc:fda.vectibix",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vectibix (panitumumab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Amgen, Inc. Vectibix (panitumumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf. Revised April 2021. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 125147,
    "company": "Amgen, Inc.",
    "drug_name_brand": "Vectibix",
    "drug_name_generic": "panitumumab",
    "first_publication_date": null,
    "publication_date": "2021-08-25",
    "status": "Active"
  },
  {
    "id": "doc:fda.keytruda",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Keytruda (pembrolizumab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf. Revised July 2025. Accessed September 2, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 125514,
    "company": "Merck Sharp & Dohme Corp.",
    "drug_name_brand": "Keytruda",
    "drug_name_generic": "pembrolizumab",
    "first_publication_date": "2014-09-04",
    "publication_date": "2025-07-24",
    "status": "Active"
  },
  {
    "id": "doc:fda.pemazyre",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pemazyre (pemigatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213736"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 213736,
    "company": "Incyte Corporation.",
    "drug_name_brand": "Pemazyre",
    "drug_name_generic": "pemigatinib",
    "first_publication_date": null,
    "publication_date": "2020-04-17",
    "status": "Active"
  },
  {
    "id": "doc:fda.perjeta",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Perjeta (pertuzumab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 125409,
    "company": "Genentech, Inc.",
    "drug_name_brand": "Perjeta",
    "drug_name_generic": "pertuzumab",
    "first_publication_date": null,
    "publication_date": "2020-01-16",
    "status": "Active"
  },
  {
    "id": "doc:fda.phesgo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761170,
    "company": "Genentech, Inc.",
    "drug_name_brand": "Phesgo",
    "drug_name_generic": "pertuzumab and trastuzumab",
    "first_publication_date": null,
    "publication_date": "2020-06-29",
    "status": "Active"
  },
  {
    "id": "doc:fda.iclusig",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Iclusig (ponatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 203469,
    "company": "Takeda Pharmaceuticals America, Inc.",
    "drug_name_brand": "Iclusig",
    "drug_name_generic": "ponatinib",
    "first_publication_date": "2012-12-14",
    "publication_date": "2024-03-19",
    "status": "Active"
  },
  {
    "id": "doc:fda.gavreto",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Gavreto (pralsetinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf. Revised March 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213721"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 213721,
    "company": "Blueprint Medicines Corporation.",
    "drug_name_brand": "Gavreto",
    "drug_name_generic": "pralsetinib",
    "first_publication_date": null,
    "publication_date": "2024-03-22",
    "status": "Active"
  },
  {
    "id": "doc:fda.cyramza",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Cyramza (ramucirumab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Eli and Lily Company. Cyramza (ramucirumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf. Revised March 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 125477,
    "company": "Eli and Lily Company.",
    "drug_name_brand": "Cyramza",
    "drug_name_generic": "ramucirumab",
    "first_publication_date": null,
    "publication_date": "2022-03-22",
    "status": "Active"
  },
  {
    "id": "doc:fda.augtyro",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Augtyro (repotrectinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf. Revised June 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218213"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 218213,
    "company": "Bristol-Myers Squibb.",
    "drug_name_brand": "Augtyro",
    "drug_name_generic": "repotrectinib",
    "first_publication_date": null,
    "publication_date": "2024-06-13",
    "status": "Active"
  },
  {
    "id": "doc:fda.kisqali",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Kisqali (ribociclib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 209092,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Kisqali",
    "drug_name_generic": "ribociclib",
    "first_publication_date": "2017-03-13",
    "publication_date": "2024-09-17",
    "status": "Active"
  },
  {
    "id": "doc:fda.rituxan",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rituxan (rituximab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 103705,
    "company": "Genentech, Inc.",
    "drug_name_brand": "Rituxan",
    "drug_name_generic": "rituximab",
    "first_publication_date": null,
    "publication_date": "2021-12-17",
    "status": "Active"
  },
  {
    "id": "doc:fda.rubraca",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rubraca (rucaparib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf. Revised December 2025. Accessed December 23, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 209115,
    "company": "Clovis Oncology, Inc.",
    "drug_name_brand": "Rubraca",
    "drug_name_generic": "rucaparib",
    "first_publication_date": null,
    "publication_date": "2025-12-17",
    "status": "Active"
  },
  {
    "id": "doc:fda.trodelvy",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trodelvy (sacituzumab govitecan) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Gilead Sciences, Inc. Trodelvy (sacituzumab govitecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf. Revised February 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761115,
    "company": "Gilead Sciences, Inc.",
    "drug_name_brand": "Trodelvy",
    "drug_name_generic": "sacituzumab govitecan",
    "first_publication_date": null,
    "publication_date": "2023-02-03",
    "status": "Active"
  },
  {
    "id": "doc:fda.retevmo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Retevmo (selpercatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Eli Lilly and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf. Revised September 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 213246,
    "company": "Eli Lilly and Company.",
    "drug_name_brand": "Retevmo",
    "drug_name_generic": "selpercatinib",
    "first_publication_date": "2020-05-08",
    "publication_date": "2024-09-27",
    "status": "Active"
  },
  {
    "id": "doc:fda.lumakras",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lumakras (sotorasib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Amgen, Inc. Lumakras (sotorasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s004lbl.pdf. Revised April 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s004lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214665"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 214665,
    "company": "Amgen, Inc.",
    "drug_name_brand": "Lumakras",
    "drug_name_generic": "sotorasib",
    "first_publication_date": null,
    "publication_date": "2023-04-23",
    "status": "Active"
  },
  {
    "id": "doc:fda.talzenna",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Talzenna (talazoparib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 211651,
    "company": "Pfizer, Inc.",
    "drug_name_brand": "Talzenna",
    "drug_name_generic": "talazoparib",
    "first_publication_date": null,
    "publication_date": "2024-02-06",
    "status": "Active"
  },
  {
    "id": "doc:fda.tazverik",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tazverik (tazemetostat) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 211723,
    "company": "Epizyme, Inc.",
    "drug_name_brand": "Tazverik",
    "drug_name_generic": "tazemetostat",
    "first_publication_date": null,
    "publication_date": "2023-11-16",
    "status": "Active"
  },
  {
    "id": "doc:fda.tepmetko",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tepmetko (tepotinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214096"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 214096,
    "company": "EMD Serono, Inc.",
    "drug_name_brand": "Tepmetko",
    "drug_name_generic": "tepotinib",
    "first_publication_date": "2021-02-03",
    "publication_date": "2024-02-15",
    "status": "Active"
  },
  {
    "id": "doc:fda.mekinist",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Mekinist (trametinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 217513,
    "company": "Novartis Pharmaceuticals Corporation.",
    "drug_name_brand": "Mekinist",
    "drug_name_generic": "trametinib",
    "first_publication_date": null,
    "publication_date": "2024-03-29",
    "status": "Active"
  },
  {
    "id": "doc:fda.herceptin",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Herceptin (trastuzumab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf. Revised June 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103792"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 103792,
    "company": "Genentech, Inc.",
    "drug_name_brand": "Herceptin",
    "drug_name_generic": "trastuzumab",
    "first_publication_date": null,
    "publication_date": "2024-06-18",
    "status": "Active"
  },
  {
    "id": "doc:fda.enhertu",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Enhertu (trastuzumab deruxtecan) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf. Revised December 2025. Accessed December 24, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761139s038s042lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761139,
    "company": "Daiichi Sankyo, Inc.",
    "drug_name_brand": "Enhertu",
    "drug_name_generic": "trastuzumab deruxtecan",
    "first_publication_date": "2019-12-20",
    "publication_date": "2025-12-15",
    "status": "Active"
  },
  {
    "id": "doc:fda.imjudo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Imjudo (tremelimumab-actl) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761270,
    "company": "AstraZeneca AB.",
    "drug_name_brand": "Imjudo",
    "drug_name_generic": "tremelimumab-actl",
    "first_publication_date": null,
    "publication_date": "2022-11-10",
    "status": "Active"
  },
  {
    "id": "doc:fda.tukysa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tukysa (tucatinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Seagen Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213411"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 213411,
    "company": "Seagen Inc.",
    "drug_name_brand": "Tukysa",
    "drug_name_generic": "tucatinib",
    "first_publication_date": null,
    "publication_date": "2023-01-19",
    "status": "Active"
  },
  {
    "id": "doc:fda.zelboraf",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Zelboraf (vemurafenib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202429"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 202429,
    "company": "Genentech, Inc.",
    "drug_name_brand": "Zelboraf",
    "drug_name_generic": "vemurafenib",
    "first_publication_date": null,
    "publication_date": "2020-05-18",
    "status": "Active"
  },
  {
    "id": "doc:fda.lazcluze",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lazcluze (lazertinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Janssen Biotech, Inc. Lazcluze (lazertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219008"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 219008,
    "company": "Janssen Biotech, Inc.",
    "drug_name_brand": "Lazcluze",
    "drug_name_generic": "lazertinib",
    "first_publication_date": "2024-08-19",
    "publication_date": "2024-08-19",
    "status": "Active"
  },
  {
    "id": "doc:fda.elahere",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Elahere (mirvetuximab soravtansine-gynx) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "ImmunoGen, Inc. Elahere (mirvetuximab soravtansine-gynx) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf. Revised March 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761310"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761310,
    "company": "ImmunoGen, Inc.",
    "drug_name_brand": "Elahere",
    "drug_name_generic": "mirvetuximab soravtansine-gynx",
    "first_publication_date": "2022-11-14",
    "publication_date": "2024-03-22",
    "status": "Active"
  },
  {
    "id": "doc:fda.ojemda",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ojemda (tovorafenib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Day One Biopharmaceuticals, Inc. Ojemda (tovorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf. Revised April 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217700"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 217700,
    "company": "Day One Biopharmaceuticals, Inc.",
    "drug_name_brand": "Ojemda",
    "drug_name_generic": "tovorafenib",
    "first_publication_date": "2024-04-23",
    "publication_date": "2024-04-23",
    "status": "Active"
  },
  {
    "id": "doc:fda.voranigo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Voranigo (vorasidenib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 218784,
    "company": "Servier Pharmaceuticals LLC.",
    "drug_name_brand": "Voranigo",
    "drug_name_generic": "vorasidenib",
    "first_publication_date": "2024-08-06",
    "publication_date": "2024-08-06",
    "status": "Active"
  },
  {
    "id": "doc:fda.itovebi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Itovebi (inavolisib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Genentech, Inc. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219249"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 219249,
    "company": "Genentech, Inc.",
    "drug_name_brand": "Itovebi",
    "drug_name_generic": "inavolisib",
    "first_publication_date": "2024-10-10",
    "publication_date": "2024-10-10",
    "status": "Active"
  },
  {
    "id": "doc:fda.vyloy",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vyloy (zolbetuximab) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Astellas Pharma US, Inc. Vyloy (zolbetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761365"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761365,
    "company": "Astellas Pharma US, Inc.",
    "drug_name_brand": "Vyloy",
    "drug_name_generic": "zolbetuximab",
    "first_publication_date": "2024-10-18",
    "publication_date": "2024-10-18",
    "status": "Active"
  },
  {
    "id": "doc:fda.ziihera",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ziihera (zanidatamab-hrii) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Astellas Pharma US, Inc. Ziihera (zanidatamab-hrii) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf. Revised November 2024. Accessed January 10, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761416"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761416,
    "company": "Astellas Pharma US, Inc.",
    "drug_name_brand": "Ziihera",
    "drug_name_generic": "zanidatamab-hrii",
    "first_publication_date": "2024-11-20",
    "publication_date": "2024-11-20",
    "status": "Active"
  },
  {
    "id": "doc:fda.bizengri",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Bizengri (zenocutuzumab-zbco) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Merus N.V. Bizengri (zenocutuzumab-zbco) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf. Revised December 2024. Accessed January 10, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761352"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761352,
    "company": "Merus N.V.",
    "drug_name_brand": "Bizengri",
    "drug_name_generic": "zenocutuzumab-zbco",
    "first_publication_date": "2024-12-04",
    "publication_date": "2024-12-04",
    "status": "Active"
  },
  {
    "id": "doc:fda.ensacove",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ensacove (ensartinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Xcovery Holdings, Inc. Ensacove (ensartinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf. Revised December 2024. Accessed January 10, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218171"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 218171,
    "company": "Xcovery Holdings, Inc.",
    "drug_name_brand": "Ensacove",
    "drug_name_generic": "ensartinib",
    "first_publication_date": "2024-12-18",
    "publication_date": "2024-12-18",
    "status": "Active"
  },
  {
    "id": "doc:fda.revuforj",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Revuforj (revumenib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf. Revised October 2025. Accessed December 26, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218944s003lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 218944,
    "company": "Syndax Pharmaceuticals, Inc.",
    "drug_name_brand": "Revuforj",
    "drug_name_generic": "revumenib",
    "first_publication_date": "2024-11-15",
    "publication_date": "2025-10-24",
    "status": "Active"
  },
  {
    "id": "doc:fda.ibtrozi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ibtrozi (taletrectinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Nuvation Bio Inc. Ibtrozi (taletrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf. Revised June 2025. Accessed June 12, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219713"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 219713,
    "company": "Nuvation Bio Inc",
    "drug_name_brand": "Ibtrozi",
    "drug_name_generic": "taletrectinib",
    "first_publication_date": "2025-06-11",
    "publication_date": "2025-06-11",
    "status": "Active"
  },
  {
    "id": "doc:fda.emrelis",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Emrelis (telisotuzumab vedotin-tllv) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Abbvie Inc. Emrelis (telisotuzumab vedotin-tllv) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf. Revised May 2025. Accessed June 12, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761384"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761384,
    "company": "Abbvie Inc.",
    "drug_name_brand": "Emrelis",
    "drug_name_generic": "telisotuzumab vedotin",
    "first_publication_date": "2025-05-14",
    "publication_date": "2025-05-14",
    "status": "Active"
  },
  {
    "id": "doc:fda.avmapki-fakzynja",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Avmapki Fakzynja co-pack (avutometinib potassium; defactinib hydrochloride) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Verastem Inc. Avmapki Fakzynja co-pack (avutometinib potassium; defactinib hydrochloride) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf. Revised May 2025. Accessed June 12, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219616"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 219616,
    "company": "Verastem Inc",
    "drug_name_brand": "Avmapki Fakzynja co-pack",
    "drug_name_generic": "avutometinib; defactinib",
    "first_publication_date": "2025-05-08",
    "publication_date": "2025-05-08",
    "status": "Active"
  },
  {
    "id": "doc:fda.datroway",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Datroway (datopotamab deruxtecan-dlnk) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Daiichi Sankyo, Inc. Datroway (datopotamab deruxtecan-dlnk) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf. Revised June 2025. Accessed September 2, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761464s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761464"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761464,
    "company": "Daiichi Sankyo, Inc.",
    "drug_name_brand": "Datroway",
    "drug_name_generic": "datopotamab deruxtecan-dlnk",
    "first_publication_date": "2025-06-23",
    "publication_date": "2025-06-23",
    "status": "Active"
  },
  {
    "id": "doc:fda.zegfrovy",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Zegfrovy (sunvozertinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Dizal (Jiangsu) Pharmaceutical Co., Ltd. Zegfrovy (sunvozertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219839s000lbl.pdf. Revised July 2025. Accessed September 3, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219839s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219839"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 219839,
    "company": "Dizal (Jiangsu) Pharmaceutical Co., Ltd.",
    "drug_name_brand": "Zegfrovy",
    "drug_name_generic": "sunvozertinib",
    "first_publication_date": "2025-07-02",
    "publication_date": "2025-07-02",
    "status": "Active"
  },
  {
    "id": "doc:fda.hernexeos",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Hernexeos (zongertinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Boehringer Ingelheim Pharmaceuticals, Inc. Hernexeos (zongertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219042s000lbl.pdf. Revised August 2025. Accessed September 3, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219042s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219042"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 219042,
    "company": "Boehringer Ingelheim Pharmaceuticals, Inc.",
    "drug_name_brand": "Hernexeos",
    "drug_name_generic": "sunvozertinib",
    "first_publication_date": "2025-08-08",
    "publication_date": "2025-08-08",
    "status": "Active"
  },
  {
    "id": "doc:ema.adcetris",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Adcetris (brentuximab vedotin) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Takeda Pharma A/S.",
    "drug_name_brand": "Adcetris",
    "drug_name_generic": "brentuximab vedotin",
    "first_publication_date": "2012-11-22",
    "publication_date": "2023-12-01",
    "status": "Active"
  },
  {
    "id": "doc:ema.afinitor",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Afinitor (everolimus) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Limited. Afinitor (everolimus) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf. Revised June 2022. Accessed March 11, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Limited.",
    "drug_name_brand": "Afinitor",
    "drug_name_generic": "everolimus",
    "first_publication_date": "2009-09-02",
    "publication_date": "2022-06-27",
    "status": "Active"
  },
  {
    "id": "doc:ema.akeega",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Akeega (abiraterone acetate and niraparib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Janssen-Cilag International N.V. Akeega (abiraterone acetate and niraparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf. Revised June 2023. Accessed March 5, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/akeega"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Janssen-Cilag International N.V.",
    "drug_name_brand": "Akeega",
    "drug_name_generic": "abiraterone acetate and niraparib",
    "first_publication_date": "2023-06-02",
    "publication_date": "2023-06-02",
    "status": "Active"
  },
  {
    "id": "doc:ema.alecensa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Alecensa (alectinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Alecensa (alectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Revised June 2024. Accessed October 18, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Alecensa",
    "drug_name_generic": "alectinib",
    "first_publication_date": "2017-04-11",
    "publication_date": "2024-06-19",
    "status": "Active"
  },
  {
    "id": "doc:ema.alunbrig",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Alunbrig (brigatinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Alunbrig (brigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf. Revised September 2023. Accessed March 6, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Alunbrig",
    "drug_name_generic": "brigatinib",
    "first_publication_date": "2018-11-26",
    "publication_date": "2023-09-22",
    "status": "Active"
  },
  {
    "id": "doc:ema.avastin",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Avastin (bevacizumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Mabxience Research SL. Avastin (bevacizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Revised March 2023. Accessed March 11, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/avastin"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Mabxience Research SL.",
    "drug_name_brand": "Avastin",
    "drug_name_generic": "bevacizumab",
    "first_publication_date": "2009-09-17",
    "publication_date": "2023-03-17",
    "status": "Active"
  },
  {
    "id": "doc:ema.ayvakyt",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ayvakyt (avapritinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Blueprint Medicines (Netherlands) B.V. Ayvakyt (avapritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf. Revised February 2024. Accessed March 6, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Blueprint Medicines (Netherlands) B.V.",
    "drug_name_brand": "Ayvakyt",
    "drug_name_generic": "avapritinib",
    "first_publication_date": "2020-09-30",
    "publication_date": "2024-02-06",
    "status": "Active"
  },
  {
    "id": "doc:ema.besponsa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Besponsa (inotuzumab ozogamicin) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Europe MA EEIG. Besponsa (inotuzumab ozogamicin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf. Revised February 2024. Accessed March 6, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Pfizer Europe MA EEIG.",
    "drug_name_brand": "Besponsa",
    "drug_name_generic": "inotuzumab ozogamicin",
    "first_publication_date": "2017-07-13",
    "publication_date": "2024-02-14",
    "status": "Active"
  },
  {
    "id": "doc:ema.blincyto",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Blincyto (blinatumomab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Amgen Europe B.V.",
    "drug_name_brand": "Blincyto",
    "drug_name_generic": "blinatumomab",
    "first_publication_date": "2015-12-07",
    "publication_date": "2025-07-23",
    "status": "Active"
  },
  {
    "id": "doc:ema.bosulif",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Bosulif (bosutinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Pfizer Europe MA EEIG.",
    "drug_name_brand": "Bosulif",
    "drug_name_generic": "bosutinib",
    "first_publication_date": "2013-04-09",
    "publication_date": "2025-08-26",
    "status": "Active"
  },
  {
    "id": "doc:ema.braftovi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Braftovi (encorafenib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Pierre Fabre Medicament. Braftovi (encorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Pierre Fabre Medicament.",
    "drug_name_brand": "Braftovi",
    "drug_name_generic": "encorafenib",
    "first_publication_date": "2018-10-12",
    "publication_date": "2024-09-05",
    "status": "Active"
  },
  {
    "id": "doc:ema.caprelsa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Caprelsa (vandetanib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Sanofi B.V. Caprelsa (vandetanib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf. Revised August 2023. Accessed March 6, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Sanofi B.V.",
    "drug_name_brand": "Caprelsa",
    "drug_name_generic": "vandetanib",
    "first_publication_date": "2012-03-02",
    "publication_date": "2023-08-16",
    "status": "Active"
  },
  {
    "id": "doc:ema.cotellic",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Cotellic (cobimetinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Cotellic (cobimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf. Revised March 2023. Accessed March 6, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Cotellic",
    "drug_name_generic": "cobimetinib",
    "first_publication_date": "2015-12-10",
    "publication_date": "2023-03-06",
    "status": "Active"
  },
  {
    "id": "doc:ema.cyramza",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Cyramza (ramucirumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Eli Lilly Nederland B.V. Cyramza (ramucirumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf. Revised December 2022. Accessed March 7, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Eli Lilly Nederland B.V.",
    "drug_name_brand": "Cyramza",
    "drug_name_generic": "ramucirumab",
    "first_publication_date": "2015-01-21",
    "publication_date": "2022-12-13",
    "status": "Active"
  },
  {
    "id": "doc:ema.taxotere",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Taxotere (docetaxel) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Sanofi Winthrop Industrie. Taxotere (docetaxel) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/taxotere"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Sanofi Winthrop Industrie.",
    "drug_name_brand": "Taxotere",
    "drug_name_generic": "docetaxel",
    "first_publication_date": "2009-01-13",
    "publication_date": "2023-12-14",
    "status": "Active"
  },
  {
    "id": "doc:ema.enhertu",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Daiichi Sankyo Europe GmbH.",
    "drug_name_brand": "Enhertu",
    "drug_name_generic": "trastuzumab deruxtecan",
    "first_publication_date": "2021-02-08",
    "publication_date": "2025-04-28",
    "status": "Active"
  },
  {
    "id": "doc:ema.erbitux",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Erbitux (cetuximab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Merck Europe B.V. Erbitux (cetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf. Revised May 2022. Accessed March 12, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Merck Europe B.V.",
    "drug_name_brand": "Erbitux",
    "drug_name_generic": "cetuximab",
    "first_publication_date": "2009-07-14",
    "publication_date": "2022-05-25",
    "status": "Active"
  },
  {
    "id": "doc:ema.faslodex",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Faslodex (fulvestrant) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca AB. Faslodex (fulvestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf. Revised August 2022. Accessed March 12, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "AstraZeneca AB.",
    "drug_name_brand": "Faslodex",
    "drug_name_generic": "fulvestrant",
    "first_publication_date": "2009-02-18",
    "publication_date": "2022-08-31",
    "status": "Active"
  },
  {
    "id": "doc:ema.gavreto",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Gavreto (pralsetinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Gavreto (pralsetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf. Revised January 2025. Accessed August 29, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Gavreto",
    "drug_name_generic": "pralsetinib",
    "first_publication_date": "2021-12-09",
    "publication_date": "2025-01-17",
    "status": "Deprecated"
  },
  {
    "id": "doc:ema.iressa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Iressa (gefitinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca AB. Iressa (gefitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf. Revised July 2023. Accessed March 7, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/iressa"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "AstraZeneca AB.",
    "drug_name_brand": "Iressa",
    "drug_name_generic": "gefitinib",
    "first_publication_date": "2009-07-22",
    "publication_date": "2023-07-17",
    "status": "Active"
  },
  {
    "id": "doc:ema.giotrif",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Giotrif (afatinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Boehringer Ingelheim International GmbH. Giotrif (afatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf. Revised June 2023. Accessed March 7, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Boehringer Ingelheim International GmbH.",
    "drug_name_brand": "Giotrif",
    "drug_name_generic": "afatinib",
    "first_publication_date": "2013-10-16",
    "publication_date": "2023-06-21",
    "status": "Active"
  },
  {
    "id": "doc:ema.herceptin",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Herceptin (trastuzumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/herceptin"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Herceptin",
    "drug_name_generic": "trastuzumab",
    "first_publication_date": "2010-03-01",
    "publication_date": "2023-03-17",
    "status": "Active"
  },
  {
    "id": "doc:ema.ibrance",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ibrance (palbociclib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Pfizer Europe MA EEIG.",
    "drug_name_brand": "Ibrance",
    "drug_name_generic": "palbociclib",
    "first_publication_date": "2016-11-25",
    "publication_date": "2023-06-06",
    "status": "Active"
  },
  {
    "id": "doc:ema.glivec",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Glivec (imatinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/glivec"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Limited.",
    "drug_name_brand": "Glivec",
    "drug_name_generic": "imatinib",
    "first_publication_date": "2009-08-18",
    "publication_date": "2023-11-20",
    "status": "Active"
  },
  {
    "id": "doc:ema.iclusig",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Iclusig (ponatinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Incyte Biosciences Distribution B.V. Iclusig (ponatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf. Revised October 2022. Accessed March 7, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Incyte Biosciences Distribution B.V.",
    "drug_name_brand": "Iclusig",
    "drug_name_generic": "ponatinib",
    "first_publication_date": "2013-07-11",
    "publication_date": "2022-10-21",
    "status": "Active"
  },
  {
    "id": "doc:ema.imfinzi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Imfinzi (durvalumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "AstraZeneca AB.",
    "drug_name_brand": "Imfinzi",
    "drug_name_generic": "durvalumab",
    "first_publication_date": "2018-10-30",
    "publication_date": "2025-07-11",
    "status": "Active"
  },
  {
    "id": "doc:ema.imjudo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Imjudo (tremelimumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca AB. Imjudo (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf. Revised March 2024. Accessed March 13, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/imjudo"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "AstraZeneca AB.",
    "drug_name_brand": "Imjudo",
    "drug_name_generic": "tremelimumab",
    "first_publication_date": "2023-03-02",
    "publication_date": "2024-03-13",
    "status": "Active"
  },
  {
    "id": "doc:ema.jemperli",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Jemperli (dostarlimab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "GlaxoSmithKline (Ireland) Limited.",
    "drug_name_brand": "Jemperli",
    "drug_name_generic": "dostarlimab",
    "first_publication_date": "2021-05-03",
    "publication_date": "2025-06-24",
    "status": "Active"
  },
  {
    "id": "doc:ema.keytruda",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Keytruda (pembrolizumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Merck Sharp & Dohme B.V.",
    "drug_name_brand": "Keytruda",
    "drug_name_generic": "pembrolizumab",
    "first_publication_date": "2015-07-30",
    "publication_date": "2024-01-11",
    "status": "Active"
  },
  {
    "id": "doc:ema.kadcyla",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Kadcyla (trastuzumab emtansine) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Kadcyla (trastuzumab emtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. Revised March 2023. Accessed March 19, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Kadcyla",
    "drug_name_generic": "trastuzumab emtansine",
    "first_publication_date": "2013-12-19",
    "publication_date": "2023-03-22",
    "status": "Active"
  },
  {
    "id": "doc:ema.kisqali",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Kisqali (ribociclib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised April 2025. Accessed September 4, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Limited.",
    "drug_name_brand": "Kisqali",
    "drug_name_generic": "ribociclib",
    "first_publication_date": "2017-08-31",
    "publication_date": "2025-04-24",
    "status": "Active"
  },
  {
    "id": "doc:ema.krazati",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Krazati (adagrasib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Mirati Therapeutics B.V. Krazati (adagrasib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/krazati"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Mirati Therapeutics B.V.",
    "drug_name_brand": "Krazati",
    "drug_name_generic": "adagrasib",
    "first_publication_date": "2024-03-13",
    "publication_date": "2024-03-13",
    "status": "Active"
  },
  {
    "id": "doc:ema.libtayo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Libtayo (cemiplimab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Regeneron Ireland Designated Activity Company (DAC). Libtayo (cemiplimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Regeneron Ireland Designated Activity Company (DAC).",
    "drug_name_brand": "Libtayo",
    "drug_name_generic": "cemiplimab",
    "first_publication_date": "2019-07-05",
    "publication_date": "2024-01-12",
    "status": "Active"
  },
  {
    "id": "doc:ema.lorviqua",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lorviqua (lorlatinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Europe MA EEIG. Lorviqua (lorlatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Pfizer Europe MA EEIG.",
    "drug_name_brand": "Lorviqua",
    "drug_name_generic": "lorlatinib",
    "first_publication_date": "2019-06-17",
    "publication_date": "2024-01-12",
    "status": "Active"
  },
  {
    "id": "doc:ema.lumykras",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lumykras (sotorasib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Amgen Europe BV. Lumykras (sotorasib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf. Revised February 2024. Accessed March 19, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Amgen Europe BV.",
    "drug_name_brand": "Lumykras",
    "drug_name_generic": "sotorasib",
    "first_publication_date": "2022-03-31",
    "publication_date": "2024-02-27",
    "status": "Active"
  },
  {
    "id": "doc:ema.lynparza",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lynparza (olaparib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "AstraZeneca AB.",
    "drug_name_brand": "Lynparza",
    "drug_name_generic": "olaparib",
    "first_publication_date": "2015-01-09",
    "publication_date": "2024-08-20",
    "status": "Active"
  },
  {
    "id": "doc:ema.lytgobi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lytgobi (futibatinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Taiho Pharma Netherlands B.V. Lytgobi (futibatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/lytgobi"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Taiho Pharma Netherlands B.V.",
    "drug_name_brand": "Lytgobi",
    "drug_name_generic": "futibatinib",
    "first_publication_date": "2023-07-18",
    "publication_date": "2023-10-19",
    "status": "Active"
  },
  {
    "id": "doc:ema.mabthera",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "MabThera (rituximab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "MabThera",
    "drug_name_generic": "rituximab",
    "first_publication_date": "2009-10-30",
    "publication_date": "2023-11-29",
    "status": "Active"
  },
  {
    "id": "doc:ema.mekinist",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Mekinist (trametinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Limited.",
    "drug_name_brand": "Mekinist",
    "drug_name_generic": "trametinib",
    "first_publication_date": "2014-07-09",
    "publication_date": "2024-03-07",
    "status": "Active"
  },
  {
    "id": "doc:ema.mektovi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Mektovi (binimetinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Pierre Fabre Medicament. Mektovi (binimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Pierre Fabre Medicament.",
    "drug_name_brand": "Mektovi",
    "drug_name_generic": "binimetinib",
    "first_publication_date": "2018-10-12",
    "publication_date": "2024-09-05",
    "status": "Active"
  },
  {
    "id": "doc:ema.mylotarg",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Mylotarg (gemtuzumab ozogamicin) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Europe MA EEIG. Mylotarg (gemtuzumab ozogamicin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf. Revised November 2023. Accessed March 20, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Pfizer Europe MA EEIG.",
    "drug_name_brand": "Mylotarg",
    "drug_name_generic": "gemtuzumab ozogamicin",
    "first_publication_date": "2018-05-04",
    "publication_date": "2023-11-20",
    "status": "Active"
  },
  {
    "id": "doc:ema.nerlynx",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nerlynx (neratinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/nerlynx"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Pierre Fabre Medicament.",
    "drug_name_brand": "Nerlynx",
    "drug_name_generic": "neratinib",
    "first_publication_date": "2018-09-12",
    "publication_date": "2023-06-15",
    "status": "Active"
  },
  {
    "id": "doc:ema.opdivo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Opdivo (nivolumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised June 2025. Accessed September 5, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Bristol-Myers Squibb Pharma EEIG.",
    "drug_name_brand": "Opdivo",
    "drug_name_generic": "nivolumab",
    "first_publication_date": "2015-07-16",
    "publication_date": "2025-06-02",
    "status": "Active"
  },
  {
    "id": "doc:ema.opdualag",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Opdualag (relatlimab / nivolumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Pharma EEIG. Opdualag (relatlimab / nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf. Revised February 2024. Accessed March 22, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/opdualag"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Bristol-Myers Squibb Pharma EEIG.",
    "drug_name_brand": "Opdualag",
    "drug_name_generic": "relatlimab / nivolumab",
    "first_publication_date": "2022-09-20",
    "publication_date": "2024-02-21",
    "status": "Active"
  },
  {
    "id": "doc:ema.orserdu",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Orserdu (elacestrant) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Stemline Therapeutics B.V. Orserdu (elacestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf. Revised February 2024. Accessed March 22, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Stemline Therapeutics B.V.",
    "drug_name_brand": "Orserdu",
    "drug_name_generic": "elacestrant",
    "first_publication_date": "2023-11-27",
    "publication_date": "2024-02-14",
    "status": "Active"
  },
  {
    "id": "doc:ema.pemazyre",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pemazyre (pemigatinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Incyte Biosciences Distribution B.V. Pemazyre (pemigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf. Revised September 2023. Accessed March 22, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Incyte Biosciences Distribution B.V.",
    "drug_name_brand": "Pemazyre",
    "drug_name_generic": "pemigatinib",
    "first_publication_date": "2021-05-04",
    "publication_date": "2023-09-12",
    "status": "Active"
  },
  {
    "id": "doc:ema.perjeta",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Perjeta (pertuzumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Perjeta",
    "drug_name_generic": "pertuzumab",
    "first_publication_date": "2013-04-02",
    "publication_date": "2024-04-05",
    "status": "Active"
  },
  {
    "id": "doc:ema.phesgo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/phesgo"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Phesgo",
    "drug_name_generic": "pertuzumab / trastuzumab",
    "first_publication_date": "2021-01-13",
    "publication_date": "2022-03-02",
    "status": "Active"
  },
  {
    "id": "doc:ema.piqray",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Piqray (alpelisib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Limited. Piqray (alpelisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf. Revised October 2023. Accessed March 22, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/piqray"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Limited.",
    "drug_name_brand": "Piqray",
    "drug_name_generic": "alpelisib",
    "first_publication_date": "2020-07-30",
    "publication_date": "2023-10-26",
    "status": "Active"
  },
  {
    "id": "doc:ema.retsevmo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Retsevmo (selpercatinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Eli Lilly Nederland B.V.",
    "drug_name_brand": "Retsevmo",
    "drug_name_generic": "selpercatinib",
    "first_publication_date": "2021-04-23",
    "publication_date": "2024-05-28",
    "status": "Active"
  },
  {
    "id": "doc:ema.revlimid",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Revlimid (lenalidomide) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Pharma EEIG. Revlimid (lenalidomide) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf. Revised January 2024. Accessed March 28, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Bristol-Myers Squibb Pharma EEIG.",
    "drug_name_brand": "Revlimid",
    "drug_name_generic": "lenalidomide",
    "first_publication_date": "2009-10-29",
    "publication_date": "2024-01-08",
    "status": "Active"
  },
  {
    "id": "doc:ema.rozlytrek",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rozlytrek (entrectinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Rozlytrek (entrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Rozlytrek",
    "drug_name_generic": "entrectinib",
    "first_publication_date": "2020-09-11",
    "publication_date": "2024-07-03",
    "status": "Active"
  },
  {
    "id": "doc:ema.rydapt",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rydapt (midostaurin) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Ltd. Rydapt (midostaurin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Ltd.",
    "drug_name_brand": "Rydapt",
    "drug_name_generic": "midostaurin",
    "first_publication_date": "2017-10-25",
    "publication_date": "2023-07-26",
    "status": "Active"
  },
  {
    "id": "doc:ema.scemblix",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Scemblix (asciminib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Ltd. Scemblix (asciminib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf. Revised January 2024. Accessed March 22, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Ltd.",
    "drug_name_brand": "Scemblix",
    "drug_name_generic": "asciminib",
    "first_publication_date": "2022-09-07",
    "publication_date": "2024-01-12",
    "status": "Active"
  },
  {
    "id": "doc:ema.spexotras",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Spexotras (trametinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Limited. Spexotras (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf. Revised January 2024. Accessed March 28, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/spexotras"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Limited.",
    "drug_name_brand": "Spexotras",
    "drug_name_generic": "trametinib",
    "first_publication_date": "2024-01-17",
    "publication_date": "2024-01-17",
    "status": "Active"
  },
  {
    "id": "doc:ema.sprycel",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Sprycel (dasatinib [anhydrous]) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Bristol-Myers Squibb Pharma EEIG.",
    "drug_name_brand": "Sprycel",
    "drug_name_generic": "dasatinib",
    "first_publication_date": "2009-08-18",
    "publication_date": "2022-06-17",
    "status": "Active"
  },
  {
    "id": "doc:ema.tabrecta",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tabrecta (capmatinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Limited. Tabrecta (capmatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf. Revised January 2023. Accessed March 23, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Limited.",
    "drug_name_brand": "Tabrecta",
    "drug_name_generic": "capmatinib",
    "first_publication_date": "2022-09-21",
    "publication_date": "2023-01-25",
    "status": "Active"
  },
  {
    "id": "doc:ema.tafinlar",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tafinlar (dabrafenib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Limited.",
    "drug_name_brand": "Tafinlar",
    "drug_name_generic": "dabrafenib",
    "first_publication_date": "2013-09-18",
    "publication_date": "2024-03-07",
    "status": "Active"
  },
  {
    "id": "doc:ema.tagrisso",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tagrisso (osimertinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised January 2025. Accessed September 5, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "AstraZeneca AB.",
    "drug_name_brand": "Tagrisso",
    "drug_name_generic": "osimertinib",
    "first_publication_date": "2016-02-17",
    "publication_date": "2025-09-05",
    "status": "Active"
  },
  {
    "id": "doc:ema.talzenna",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Talzenna (talazoparib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Europe MA EEIG. Talzenna (talazoparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Pfizer Europe MA EEIG.",
    "drug_name_brand": "Talzenna",
    "drug_name_generic": "talazoparib",
    "first_publication_date": "2019-07-08",
    "publication_date": "2024-01-16",
    "status": "Active"
  },
  {
    "id": "doc:ema.tarceva",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tarceva (erlotinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Tarceva (erlotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf. Revised May 2023. Accessed March 23, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Tarceva",
    "drug_name_generic": "erlotinib",
    "first_publication_date": "2009-07-14",
    "publication_date": "2023-05-16",
    "status": "Active"
  },
  {
    "id": "doc:ema.tasigna",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tasigna (nilotinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Limited. Tasigna (nilotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Limited.",
    "drug_name_brand": "Tasigna",
    "drug_name_generic": "nilotinib",
    "first_publication_date": "2009-09-29",
    "publication_date": "2023-11-27",
    "status": "Active"
  },
  {
    "id": "doc:ema.tecentriq",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tecentriq (atezolizumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Tecentriq",
    "drug_name_generic": "atezolizumab",
    "first_publication_date": "2017-09-29",
    "publication_date": "2024-03-25",
    "status": "Active"
  },
  {
    "id": "doc:ema.tepmetko",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tepmetko (tepotinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Merck Europe B.V. Tepmetko (tepotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Merck Europe B.V.",
    "drug_name_brand": "Tepmetko",
    "drug_name_generic": "tepotinib",
    "first_publication_date": "2022-05-05",
    "publication_date": "2023-11-20",
    "status": "Active"
  },
  {
    "id": "doc:ema.tibsovo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tibsovo (ivosidenib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Les Laboratoires Servier.",
    "drug_name_brand": "Tibsovo",
    "drug_name_generic": "ivosidenib",
    "first_publication_date": "2023-05-12",
    "publication_date": "2024-01-15",
    "status": "Active"
  },
  {
    "id": "doc:ema.tremelimumab-astrazeneca",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tremelimumab-astrazeneca"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "AstraZeneca AB.",
    "drug_name_brand": "Tremelimumab AstraZeneca",
    "drug_name_generic": "tremelimumab",
    "first_publication_date": "2023-04-04",
    "publication_date": "2024-08-22",
    "status": "Deprecated"
  },
  {
    "id": "doc:ema.trisenox",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trisenox (arsenic trioxide) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Teva B.V. Trisenox (arsenic trioxide) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/trisenox"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Teva B.V.",
    "drug_name_brand": "Trisenox",
    "drug_name_generic": "arsenic trioxide",
    "first_publication_date": "2009-10-08",
    "publication_date": "2023-05-25",
    "status": "Active"
  },
  {
    "id": "doc:ema.trodelvy",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trodelvy (sacituzumab govitecan) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Gilead Sciences Ireland UC. Trodelvy (sacituzumab govitecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Gilead Sciences Ireland UC.",
    "drug_name_brand": "Trodelvy",
    "drug_name_generic": "sacituzumab govitecan",
    "first_publication_date": "2021-11-24",
    "publication_date": "2023-08-11",
    "status": "Active"
  },
  {
    "id": "doc:ema.tukysa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tukysa (tucatinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Seagen B.V. Tukysa (tucatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Seagen B.V.",
    "drug_name_brand": "Tukysa",
    "drug_name_generic": "tucatinib",
    "first_publication_date": "2021-02-18",
    "publication_date": "2023-08-21",
    "status": "Active"
  },
  {
    "id": "doc:ema.tyverb",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tyverb (lapatinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Limited.",
    "drug_name_brand": "Tyverb",
    "drug_name_generic": "lapatinib",
    "first_publication_date": "2009-11-17",
    "publication_date": "2023-05-10",
    "status": "Active"
  },
  {
    "id": "doc:ema.vectibix",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vectibix (panitumumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Amgen Europe B.V.",
    "drug_name_brand": "Vectibix",
    "drug_name_generic": "panitumumab",
    "first_publication_date": "2009-06-18",
    "publication_date": "2022-07-06",
    "status": "Active"
  },
  {
    "id": "doc:ema.venclyxto",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Venclyxto (venetoclax) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "AbbVie Deutschland GmbH Co. KG.",
    "drug_name_brand": "Venclyxto",
    "drug_name_generic": "venetoclax",
    "first_publication_date": "2016-12-21",
    "publication_date": "2023-10-31",
    "status": "Active"
  },
  {
    "id": "doc:ema.verzenios",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Verzenios (abemaciclib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Eli Lilly Nederland B.V.",
    "drug_name_brand": "Verzenios",
    "drug_name_generic": "abemaciclib",
    "first_publication_date": "2018-10-29",
    "publication_date": "2024-03-12",
    "status": "Active"
  },
  {
    "id": "doc:ema.vitrakvi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vitrakvi (larotrectinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Bayer AG. Vitrakvi (larotrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Bayer AG.",
    "drug_name_brand": "Vitrakvi",
    "drug_name_generic": "larotrectinib",
    "first_publication_date": "2019-10-24",
    "publication_date": "2023-09-22",
    "status": "Active"
  },
  {
    "id": "doc:ema.vizimpro",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vizimpro (dacomitinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Europe MA EEIG. Vizimpro (dacomitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf. Revised February 2024. Accessed March 25, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Pfizer Europe MA EEIG.",
    "drug_name_brand": "Vizimpro",
    "drug_name_generic": "dacomitinib",
    "first_publication_date": "2019-06-05",
    "publication_date": "2024-02-21",
    "status": "Active"
  },
  {
    "id": "doc:ema.xalkori",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Xalkori (crizotinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Pfizer Europe MA EEIG.",
    "drug_name_brand": "Xalkori",
    "drug_name_generic": "crizotinib",
    "first_publication_date": "2012-11-14",
    "publication_date": "2024-09-24",
    "status": "Active"
  },
  {
    "id": "doc:ema.xospata",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Xospata (gilteritinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Astellas Pharma Europe B.V. Xospata (gilteritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf. Revised November 2023. Accessed March 26, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/xospata"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Astellas Pharma Europe B.V.",
    "drug_name_brand": "Xospata",
    "drug_name_generic": "gilteritinib",
    "first_publication_date": "2019-11-08",
    "publication_date": "2023-11-07",
    "status": "Active"
  },
  {
    "id": "doc:ema.yervoy",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Yervoy (ipilimumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2025. Accessed September 5, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Bristol-Myers Squibb Pharma EEIG.",
    "drug_name_brand": "Yervoy",
    "drug_name_generic": "ipilimumab",
    "first_publication_date": "2011-07-25",
    "publication_date": "2025-03-17",
    "status": "Active"
  },
  {
    "id": "doc:ema.zelboraf",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Zelboraf (vemurafenib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Zelboraf (vemurafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf. Revised July 2023. Accessed March 26, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH.",
    "drug_name_brand": "Zelboraf",
    "drug_name_generic": "vemurafenib",
    "first_publication_date": "2012-03-19",
    "publication_date": "2023-07-18",
    "status": "Active"
  },
  {
    "id": "doc:ema.zydelig",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Zydelig (idelalisib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Gilead Sciences Ireland UC. Zydelig (idelalisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf. Revised June 2023. Accessed March 26, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Gilead Sciences Ireland UC.",
    "drug_name_brand": "Zydelig",
    "drug_name_generic": "idelalisib",
    "first_publication_date": "2014-10-14",
    "publication_date": "2023-06-23",
    "status": "Active"
  },
  {
    "id": "doc:ema.zykadia",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Zykadia (ceritinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Europharm Limited. Zykadia (ceritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf. Revised December 2023. Accessed March 26, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Novartis Europharm Limited.",
    "drug_name_brand": "Zykadia",
    "drug_name_generic": "ceritinib",
    "first_publication_date": "2015-06-04",
    "publication_date": "2023-12-07",
    "status": "Active"
  },
  {
    "id": "doc:ema.tevimbra",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tevimbra (tislelizumab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "BeiGene Ireland Ltd. Tevimbra (tislelizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf. Revised July 2025. Accessed September 5, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/tevimbra"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "BeiGene Ireland Ltd.",
    "drug_name_brand": "Tevimbra",
    "drug_name_generic": "tislelizumab",
    "first_publication_date": "2023-10-02",
    "publication_date": "2025-07-14",
    "status": "Active"
  },
  {
    "id": "doc:ema.rybrevant",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rybrevant (amivantamab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Janssen-Cilag International N.V. Rybrevant (amivantamab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf. Revised July 2025. Accessed September 5, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Janssen-Cilag International N.V.",
    "drug_name_brand": "Rybrevant",
    "drug_name_generic": "amivantamab",
    "first_publication_date": "2022-02-01",
    "publication_date": "2025-07-18",
    "status": "Active"
  },
  {
    "id": "doc:ema.truqap",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Truqap (capivasertib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/truqap"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "AstraZeneca AB.",
    "drug_name_brand": "Truqap",
    "drug_name_generic": "capivasertib",
    "first_publication_date": "2024-07-11",
    "publication_date": "2024-07-11",
    "status": "Active"
  },
  {
    "id": "doc:ema.balversa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Balversa (erdafitinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/balversa"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Janssen-Cilag International N.V.",
    "drug_name_brand": "Balversa",
    "drug_name_generic": "erdafitinib",
    "first_publication_date": "2024-08-29",
    "publication_date": "2024-08-29",
    "status": "Active"
  },
  {
    "id": "doc:ema.vyloy",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vyloy (zolbetuximab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Astellas Pharma Europe B.V. Vyloy (zolbetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/vyloy"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Astellas Pharma Europe B.V.",
    "drug_name_brand": "Vyloy",
    "drug_name_generic": "zolbetuximab",
    "first_publication_date": "2024-09-23",
    "publication_date": "2024-09-23",
    "status": "Active"
  },
  {
    "id": "doc:ema.augtyro",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Augtyro (repotrectinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Pharma EEIG. Augtyro (repotrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/augtyro-epar-product-information_en.pdf. Revised January 2025. Accessed September 8, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/augtyro-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/augtyro"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Bristol-Myers Squibb Pharma EEIG",
    "drug_name_brand": "Augtyro",
    "drug_name_generic": "repotrectinib",
    "first_publication_date": "2025-01-28",
    "publication_date": "2025-01-28",
    "status": "Active"
  },
  {
    "id": "doc:ema.lazcluze",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lazcluze (lazertinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Janssen Cilag International NV. Lazcluze (lazertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lazcluze-epar-product-information_en.pdf. Revised January 2025. Accessed September 8, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/lazcluze-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/lazcluze"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Janssen Cilag International NV",
    "drug_name_brand": "Augtyro",
    "drug_name_generic": "repotrectinib",
    "first_publication_date": "2025-03-17",
    "publication_date": "2025-07-18",
    "status": "Active"
  },
  {
    "id": "doc:ema.elahere",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Elahere (mirvetuximab soravtansine) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "AbbVie Deutschland GmbH & Co. KG. Elahere (mirvetuximab soravtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/elahere-epar-product-information_en.pdf. Revised August 2025. Accessed September 8, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/elahere-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/elahere"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "AbbVie Deutschland GmbH & Co. KG",
    "drug_name_brand": "Elahere",
    "drug_name_generic": "mirvetuximab soravtansine",
    "first_publication_date": "2024-12-10",
    "publication_date": "2025-08-20",
    "status": "Active"
  },
  {
    "id": "doc:hc.adcetris",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Adcetris (brentuximab vedotin) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00080158.PDF",
      "https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Seagen Inc.",
    "drug_name_brand": "Adcetris",
    "drug_name_generic": "brentuximab vedotin",
    "first_publication_date": null,
    "publication_date": "2025-04-08",
    "status": "Active"
  },
  {
    "id": "doc:hc.afinitor",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Afinitor (everolimus) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00063824.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Afinitor",
    "drug_name_generic": "everolimus",
    "first_publication_date": "2009-12-11",
    "publication_date": "2021-11-30",
    "status": "Active"
  },
  {
    "id": "doc:hc.akeega",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Akeega (abiraterone acetate and niraparib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Janssen Inc. Akeega (abiraterone acetate and niraparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078864.PDF. Revised March 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078864.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102726"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Janssen Inc.",
    "drug_name_brand": "Akeega",
    "drug_name_generic": "abiraterone acetate and niraparib",
    "first_publication_date": "2023-06-07",
    "publication_date": "2025-03-12",
    "status": "Active"
  },
  {
    "id": "doc:hc.alecensaro",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Alecensaro (alectinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Hoffmann-La Roche Limited. Alecensaro (alectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078825.PDF. Revised March 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078825.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94518"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Alecensaro",
    "drug_name_generic": "alectinib",
    "first_publication_date": "2016-09-29",
    "publication_date": "2025-03-11",
    "status": "Active"
  },
  {
    "id": "doc:hc.alunbrig",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Alunbrig (brigatinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Takeda Canada Inc. Alunbrig (brigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00066731.PDF. Revised July 2022. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00066731.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96982"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Takeda Canada Inc.",
    "drug_name_brand": "Alunbrig",
    "drug_name_generic": "brigatinib",
    "first_publication_date": "2018-07-25",
    "publication_date": "2022-07-19",
    "status": "Active"
  },
  {
    "id": "doc:hc.augtyro",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Augtyro (repotrectinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Canada. Augtyro (repotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080483.PDF. Published May 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00080483.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106076"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Bristol-Myers Squibb Canada",
    "drug_name_brand": "Augtyro",
    "drug_name_generic": "repotrectinib",
    "first_publication_date": "2025-05-07",
    "publication_date": "2025-05-07",
    "status": "Active"
  },
  {
    "id": "doc:hc.balversa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Balversa (erdafitinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00077812.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Janssen Inc.",
    "drug_name_brand": "Balversa",
    "drug_name_generic": "erdafitinib",
    "first_publication_date": "2019-10-25",
    "publication_date": "2024-11-20",
    "status": "Active"
  },
  {
    "id": "doc:hc.besponsa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Besponsa (inotuzumab ozogamicin) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Canada ULC. Besponsa (inotuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077730.PDF. Revised November 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00077730.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96383"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Besponsa",
    "drug_name_generic": "inotuzumab ozogamicin",
    "first_publication_date": "2018-03-15",
    "publication_date": "2024-11-08",
    "status": "Active"
  },
  {
    "id": "doc:hc.blincyto",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Blincyto (blinatumomab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Amgen Canada Inc. Blincyto (blinatumomab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078156.PDF. Revised December 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078156.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93642"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Amgen Canada Inc.",
    "drug_name_brand": "Blincyto",
    "drug_name_generic": "blinatumomab",
    "first_publication_date": "2015-12-22",
    "publication_date": "2024-12-27",
    "status": "Active"
  },
  {
    "id": "doc:hc.bosulif",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Bosulif (bosutinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Canada ULC. Bosulif (bosutinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076285.PDF. Revised July 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00076285.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90368"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Bosulif",
    "drug_name_generic": "bosutinib",
    "first_publication_date": "2014-03-07",
    "publication_date": "2024-07-12",
    "status": "Active"
  },
  {
    "id": "doc:hc.braftovi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Braftovi (encorafenib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00074711.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100233"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Braftovi",
    "drug_name_generic": "encorafenib",
    "first_publication_date": "2021-03-02",
    "publication_date": "2024-02-23",
    "status": "Active"
  },
  {
    "id": "doc:hc.cotellic",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Cotellic (cobimetinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Hoffmann-La Roche Limited. Cotellic (cobimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070061.PDF. Revised March 2023. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00070061.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93872"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Cotellic",
    "drug_name_generic": "cobimetinib",
    "first_publication_date": "2016-02-22",
    "publication_date": "2023-03-24",
    "status": "Active"
  },
  {
    "id": "doc:hc.enhertu",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Enhertu (trastuzumab deruxtecan) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078361.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Enhertu",
    "drug_name_generic": "trastuzumab deruxtecan",
    "first_publication_date": "2021-04-15",
    "publication_date": "2025-01-17",
    "status": "Active"
  },
  {
    "id": "doc:hc.erbitux",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Erbitux (cetuximab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00043071.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "ImClone LLC",
    "drug_name_brand": "Erbitux",
    "drug_name_generic": "cetuximab",
    "first_publication_date": "2018-01-10",
    "publication_date": "2018-01-10",
    "status": "Active"
  },
  {
    "id": "doc:hc.faslodex",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Faslodex (fulvestrant) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca Canada Inc. Faslodex (fulvestrant) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00053975.PDF. Revised November 2019. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00053975.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72981"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Faslodex",
    "drug_name_generic": "fulvestrant",
    "first_publication_date": null,
    "publication_date": "2019-11-15",
    "status": "Active"
  },
  {
    "id": "doc:hc.giotrif",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Giotrif (afatinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00051644.PDF. Revised June 2019. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00051644.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90026"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Boehringer Ingelheim (Canada) Ltd",
    "drug_name_brand": "Giotrif",
    "drug_name_generic": "afatinib",
    "first_publication_date": null,
    "publication_date": "2019-06-06",
    "status": "Active"
  },
  {
    "id": "doc:hc.gleevec",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Gleevec (imatinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00067276.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Gleevec",
    "drug_name_generic": "imatinib",
    "first_publication_date": "2001-09-19",
    "publication_date": "2021-08-31",
    "status": "Active"
  },
  {
    "id": "doc:hc.herceptin",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Herceptin (trastuzumab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00080472.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Herceptin",
    "drug_name_generic": "trastuzumab",
    "first_publication_date": "1999-08-13",
    "publication_date": "2025-05-02",
    "status": "Active"
  },
  {
    "id": "doc:hc.ibrance",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ibrance (palbociclib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00080011.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Ibrance",
    "drug_name_generic": "palbociclib",
    "first_publication_date": "2016-03-15",
    "publication_date": "2025-03-24",
    "status": "Active"
  },
  {
    "id": "doc:hc.iclusig",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Iclusig (ponatinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Takeda Pharmaceuticals U.S.A., Inc. Iclusig (ponatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078669.PDF. Revised February. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078669.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92168"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Takeda Pharmaceuticals U.S.A., Inc.",
    "drug_name_brand": "Iclusig",
    "drug_name_generic": "ponatinib",
    "first_publication_date": "2015-03-31",
    "publication_date": "2025-02-24",
    "status": "Active"
  },
  {
    "id": "doc:hc.imfinzi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Imfinzi (durvalumab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080178.PDF. Revised April 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00080178.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Imfinzi",
    "drug_name_generic": "durvalumab",
    "first_publication_date": "2017-11-03",
    "publication_date": "2025-04-10",
    "status": "Active"
  },
  {
    "id": "doc:hc.iressa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Iressa (gefitinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00060650.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Iressa",
    "drug_name_generic": "gefitinib",
    "first_publication_date": "2003-12-17",
    "publication_date": "2021-03-31",
    "status": "Active"
  },
  {
    "id": "doc:hc.itovebi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Itovebi (inavolisib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078611.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Itovebi",
    "drug_name_generic": "inavolisib",
    "first_publication_date": "2025-02-14",
    "publication_date": "2025-02-14",
    "status": "Active"
  },
  {
    "id": "doc:hc.jemperli",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Jemperli (dostarlimab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "GlaxoSmithKline Inc. Jemperli (dostarlimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080289.PDF. Published April 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00080289.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101252"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "GlaxoSmithKline Inc.",
    "drug_name_brand": "Jemperli",
    "drug_name_generic": "dostarlimab",
    "first_publication_date": "2025-04-06",
    "publication_date": "2025-04-16",
    "status": "Active"
  },
  {
    "id": "doc:hc.kadcyla",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Kadcyla (ado-trastuzumab emtansine) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00067729.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89698"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Kadcyla",
    "drug_name_generic": "ado-trastuzumab emtansine",
    "first_publication_date": "2013-09-11",
    "publication_date": "2022-10-13",
    "status": "Active"
  },
  {
    "id": "doc:hc.keytruda",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Keytruda (pembrolizumab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00080285.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Merck Canada Inc.",
    "drug_name_brand": "Keytruda",
    "drug_name_generic": "pembrolizumab",
    "first_publication_date": "2025-04-11",
    "publication_date": "2025-04-11",
    "status": "Active"
  },
  {
    "id": "doc:hc.kisqali",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Kisqali (ribociclib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00075798.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96295"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Kisqali",
    "drug_name_generic": "ribociclib",
    "first_publication_date": "2018-03-02",
    "publication_date": "2024-05-31",
    "status": "Active"
  },
  {
    "id": "doc:hc.lazcluze",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lazcluze (lazertinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Janssen Inc. Lazcluze (lazertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078792.PDF. Published March 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078792.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Janssen Inc.",
    "drug_name_brand": "Lazcluze",
    "drug_name_generic": "lazertinib",
    "first_publication_date": "2025-03-06",
    "publication_date": "2025-03-06",
    "status": "Active"
  },
  {
    "id": "doc:hc.libtayo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Libtayo (cemiplimab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Regeneron Canada Company. Libtayo (cemiplimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078455.PDF. Revised January 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078455.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97728"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Regeneron Canada Company",
    "drug_name_brand": "Libtayo",
    "drug_name_generic": "cemiplimab",
    "first_publication_date": "2019-04-10",
    "publication_date": "2025-01-30",
    "status": "Active"
  },
  {
    "id": "doc:hc.lorbrena",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lorbrena (lorlatinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Canada ULC. Lorbrena (lorlatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077541.PDF. Revised October 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00077541.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97619"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Lorbrena",
    "drug_name_generic": "lorlatinib",
    "first_publication_date": "2019-02-20",
    "publication_date": "2024-10-28",
    "status": "Active"
  },
  {
    "id": "doc:hc.lumakras",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lumakras (sotorasib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Amgen Canada Inc. Lumakras (sotorasib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078781.PDF. Revised March 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078781.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100931"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Amgen Canada Inc.",
    "drug_name_brand": "Lumakras",
    "drug_name_generic": "sotorasib",
    "first_publication_date": "2021-09-09",
    "publication_date": "2025-03-04",
    "status": "Active"
  },
  {
    "id": "doc:hc.lynparza",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lynparza (olaparib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00080379.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Lynparza",
    "drug_name_generic": "olaparib",
    "first_publication_date": "2025-04-29",
    "publication_date": "2025-04-29",
    "status": "Active"
  },
  {
    "id": "doc:hc.mekinist",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Mekinist (trametinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077955.PDF. Revised December 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00077955.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89431"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Mekinist",
    "drug_name_generic": "trametinib",
    "first_publication_date": "2013-07-18",
    "publication_date": "2024-12-05",
    "status": "Active"
  },
  {
    "id": "doc:hc.mektovi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Mektovi (binimetinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Canada ULC. Mektovi (binimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060288.PDF. Published March 2021. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00060288.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100232"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Mektovi",
    "drug_name_generic": "binimetinib",
    "first_publication_date": "2021-03-02",
    "publication_date": "2021-03-02",
    "status": "Active"
  },
  {
    "id": "doc:hc.mylotarg",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Mylotarg (gemtuzumab ozogamicin) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Canada ULC. Mylotarg (gemtuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00069427.PDF. Revised February 2023. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00069427.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98440"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Mylotarg",
    "drug_name_generic": "gemtuzumab ozogamicin",
    "first_publication_date": "2019-11-28",
    "publication_date": "2023-02-02",
    "status": "Active"
  },
  {
    "id": "doc:hc.nerlynx",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nerlynx (neratinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00062158.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98057"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Knight Therapeutics Inc.",
    "drug_name_brand": "Nerlynx",
    "drug_name_generic": "neratinib",
    "first_publication_date": "2019-07-15",
    "publication_date": "2021-07-16",
    "status": "Active"
  },
  {
    "id": "doc:hc.opdivo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Opdivo (nivolumab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Canada. Opdivo (nivolumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076152.PDF. Revised June 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00076152.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93204"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Bristol-Myers Squibb Canada",
    "drug_name_brand": "Opdivo",
    "drug_name_generic": "nivolumab",
    "first_publication_date": "2015-09-25",
    "publication_date": "2024-06-28",
    "status": "Active"
  },
  {
    "id": "doc:hc.pemazyre",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pemazyre (pemigatinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Pemazyre (pemigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062968.PDF. Published September 2021. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00062968.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100917"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Incyte Corporation",
    "drug_name_brand": "Pemazyre",
    "drug_name_generic": "pemigatinib",
    "first_publication_date": "2021-09-09",
    "publication_date": "2021-09-08",
    "status": "Active"
  },
  {
    "id": "doc:hc.perjeta",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Perjeta (pertuzumab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00060125.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88984"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Perjeta",
    "drug_name_generic": "pertuzumab",
    "first_publication_date": "2013-04-12",
    "publication_date": "2013-04-12",
    "status": "Active"
  },
  {
    "id": "doc:hc.phesgo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Phesgo (pertuzumab and trastuzumab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Hoffmann-La Roche Limited. Phesgo (pertuzumab and trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064237.PDF. Revised January 2022. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00064237.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100216"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Phesgo",
    "drug_name_generic": "pertuzumab and trastuzumab",
    "first_publication_date": "2021-03-01",
    "publication_date": "2022-01-05",
    "status": "Active"
  },
  {
    "id": "doc:hc.piqray",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Piqray (alpelisib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Piqray (alpelisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076641.PDF. Revised August 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00076641.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98692"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Piqray",
    "drug_name_generic": "alpelisib",
    "first_publication_date": "2020-03-11",
    "publication_date": "2024-08-12",
    "status": "Active"
  },
  {
    "id": "doc:hc.retevmo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Retevmo (selpercatinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078253.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Loxo Oncology Inc.",
    "drug_name_brand": "Retevmo",
    "drug_name_generic": "selpercatinib",
    "first_publication_date": "2021-06-11",
    "publication_date": "2025-01-10",
    "status": "Active"
  },
  {
    "id": "doc:hc.revlimid",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Revlimid (lenalidomide) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Canada. Revlimid (lenalidomide) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074535.PDF. Published February 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00074535.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79016"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Bristol-Myers Squibb Canada",
    "drug_name_brand": "Revlimid",
    "drug_name_generic": "lenalidomide",
    "first_publication_date": "2024-02-09",
    "publication_date": "2024-02-09",
    "status": "Active"
  },
  {
    "id": "doc:hc.rituxan",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rituxan (rituximab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00071131.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65597"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Rituxan",
    "drug_name_generic": "rituximab",
    "first_publication_date": "2000-03-17",
    "publication_date": "2023-06-02",
    "status": "Active"
  },
  {
    "id": "doc:hc.rozlytrek",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rozlytrek (entrectinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Hoffmann-La Roche Limited. Rozlytrek (entrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073345.PDF. Revised November 2023. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00073345.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98496"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Rozlytrek",
    "drug_name_generic": "entrectinib",
    "first_publication_date": "2020-02-07",
    "publication_date": "2023-11-09",
    "status": "Active"
  },
  {
    "id": "doc:hc.rybrevant",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rybrevant (amivantamab-vmjw) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078295.PDF. Revised January 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078295.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Janssen Inc.",
    "drug_name_brand": "Rybrevant",
    "drug_name_generic": "amivantamab-vmjw",
    "first_publication_date": "2022-03-30",
    "publication_date": "2025-01-13",
    "status": "Active"
  },
  {
    "id": "doc:hc.rydapt",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Rydapt (midostaurin) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Rydapt (midostaurin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070168.PDF. Revised March 2023. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00070168.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95454"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Rydapt",
    "drug_name_generic": "midostaurin",
    "first_publication_date": "2017-07-21",
    "publication_date": "2023-03-31",
    "status": "Active"
  },
  {
    "id": "doc:hc.scemblix",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Scemblix (asciminib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Scemblix (asciminib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076300.PDF. Revised July 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00076300.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101756"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc",
    "drug_name_brand": "Scemblix",
    "drug_name_generic": "asciminib",
    "first_publication_date": "2022-06-21",
    "publication_date": "2024-07-12",
    "status": "Active"
  },
  {
    "id": "doc:hc.sprycel",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Sprycel (dasatinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Canada. Sprycel (dasatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063441.PDF. Revised November 2021. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00063441.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77850"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Bristol-Myers Squibb Canada",
    "drug_name_brand": "Sprycel",
    "drug_name_generic": "dasatinib",
    "first_publication_date": "2007-03-22",
    "publication_date": "2021-11-03",
    "status": "Active"
  },
  {
    "id": "doc:hc.tabrecta",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tabrecta (capmatinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Tabrecta (capmatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071417.PDF. Revised June 2023. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00071417.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101646"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Tabrecta",
    "drug_name_generic": "capmatinib",
    "first_publication_date": "2022-05-19",
    "publication_date": "2023-06-26",
    "status": "Active"
  },
  {
    "id": "doc:hc.tafinlar",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tafinlar (dabrafenib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077956.PDF. Revised December 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00077956.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89429"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Tafinlar",
    "drug_name_generic": "dabrafenib",
    "first_publication_date": "2013-08-23",
    "publication_date": "2024-12-05",
    "status": "Active"
  },
  {
    "id": "doc:hc.tagrisso",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tagrisso (osimertinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca Canada Inc. Tagrisso (osimertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080336.PDF. Revised April 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00080336.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94310"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Tagrisso",
    "drug_name_generic": "osimertinib",
    "first_publication_date": "2016-07-05",
    "publication_date": "2025-04-23",
    "status": "Active"
  },
  {
    "id": "doc:hc.talzenna",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Talzenna (talazoparib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Canada ULC. Talzenna (talazoparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078463.PDF. Revised January 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078463.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98204"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Talzenna",
    "drug_name_generic": "talazoparib",
    "first_publication_date": "2020-09-30",
    "publication_date": "2025-01-30",
    "status": "Active"
  },
  {
    "id": "doc:hc.tasigna",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tasigna (nilotinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Tasigna (nilotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076372.PDF. Revised July 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00076372.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80138"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Tasigna",
    "drug_name_generic": "nilotinib",
    "first_publication_date": "2008-09-30",
    "publication_date": "2024-07-17",
    "status": "Active"
  },
  {
    "id": "doc:hc.tecentriq",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tecentriq (atezolizumab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Hoffmann-La Roche Limited. Tecentriq (atezolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078266.PDF. Revised January 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078266.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95089"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Tecentriq",
    "drug_name_generic": "atezolizumab",
    "first_publication_date": "2017-04-12",
    "publication_date": "2025-01-09",
    "status": "Active"
  },
  {
    "id": "doc:hc.tepmetko",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tepmetko (tepotinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "EMD Serono, a Division of EMD Inc., Canada. Tepmetko (tepotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074821.PDF. Revised March 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00074821.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100568"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "EMD Serono, a Division of EMD Inc., Canada",
    "drug_name_brand": "Tepmetko",
    "drug_name_generic": "tepotinib",
    "first_publication_date": "2021-05-27",
    "publication_date": "2024-03-04",
    "status": "Active"
  },
  {
    "id": "doc:hc.tibsovo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tibsovo (ivosidenib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00076398.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103879"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Servier Canada Inc.",
    "drug_name_brand": "Tibsovo",
    "drug_name_generic": "ivosidenib",
    "first_publication_date": "2024-07-19",
    "publication_date": "2024-07-19",
    "status": "Active"
  },
  {
    "id": "doc:hc.trodelvy",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trodelvy (sacituzumab govitecan) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Gilead Sciences Canada, Inc. Trodelvy (sacituzumab govitecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080546.PDF. Published May 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00080546.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100997"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Gilead Sciences Canada, Inc.",
    "drug_name_brand": "Trodelvy",
    "drug_name_generic": "sacituzumab govitecan",
    "first_publication_date": "2025-05-14",
    "publication_date": "2025-05-14",
    "status": "Active"
  },
  {
    "id": "doc:hc.truqap",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Truqap (capivasertib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "AstraZeneca Canada Inc. Truqap (capivasertib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078178.PDF. Revised January 2025. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078178.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103334"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "AstraZeneca Canada Inc.",
    "drug_name_brand": "Truqap",
    "drug_name_generic": "capivasertib",
    "first_publication_date": "2024-01-24",
    "publication_date": "2025-01-03",
    "status": "Active"
  },
  {
    "id": "doc:hc.tukysa",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tukysa (tucatinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Seagen Inc. Tukysa (tucatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062119.PDF. Revised July 2021. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00062119.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98955"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Seagen Inc.",
    "drug_name_brand": "Tukysa",
    "drug_name_generic": "tucatinib",
    "first_publication_date": "2020-06-03",
    "publication_date": "2021-07-08",
    "status": "Active"
  },
  {
    "id": "doc:hc.tykerb",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tykerb (lapatinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Tykerb (lapatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064944.PDF. Revised March 2022. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00064944.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81179"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Tykerb",
    "drug_name_generic": "lapatinib",
    "first_publication_date": "2009-01-05",
    "publication_date": "2022-03-02",
    "status": "Active"
  },
  {
    "id": "doc:hc.vectibix",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vectibix (panitumumab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Amgen Canada Inc. Vectibix (panitumumab)[product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063326.PDF. Revised October 2021. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00063326.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79412"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Amgen Canada Inc.",
    "drug_name_brand": "Vectibix",
    "drug_name_generic": "panitumumab",
    "first_publication_date": "2008-04-03",
    "publication_date": "2021-10-25",
    "status": "Active"
  },
  {
    "id": "doc:hc.verzenio",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": " Verzenio (abemaciclib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Eli Lilly Canada Inc. Verzenio (abemaciclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00073683.PDF. Revised December 2023. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00073683.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97723"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Eli Lilly Canada Inc.",
    "drug_name_brand": "Verzenio",
    "drug_name_generic": "abemaciclib",
    "first_publication_date": "2019-04-04",
    "publication_date": "2023-12-01",
    "status": "Active"
  },
  {
    "id": "doc:hc.vitrakvi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vitrakvi (larotrectinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Bayer Inc. Vitrakvi (larotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076917.PDF. Revised September 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00076917.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98037"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Bayer Inc.",
    "drug_name_brand": "Vitrakvi",
    "drug_name_generic": "larotrectinib",
    "first_publication_date": "2019-07-04",
    "publication_date": "2024-09-03",
    "status": "Active"
  },
  {
    "id": "doc:hc.voranigo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Voranigo (vorasidenib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Servier Canada Inc. Voranigo (vorasidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076841.PDF. Published August 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00076841.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103996"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Servier Canada Inc.",
    "drug_name_brand": "Voranigo",
    "drug_name_generic": "vorasidenib",
    "first_publication_date": "2024-08-27",
    "publication_date": "2024-08-27",
    "status": "Active"
  },
  {
    "id": "doc:hc.vyloy",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vyloy (zolbetuximab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Astellas Pharma Canada, Inc. Vyloy (zolbetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078035.PDF. Published December 2024. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00078035.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104288"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Astellas Pharma Canada, Inc.",
    "drug_name_brand": "Vyloy",
    "drug_name_generic": "zolbetuximab",
    "first_publication_date": "2024-12-13",
    "publication_date": "2024-12-13",
    "status": "Active"
  },
  {
    "id": "doc:hc.xalkori",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Xalkori (crizotinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Canada ULC. Xalkori (crizotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070448.PDF. Revised April 2023. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00070448.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86999"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Pfizer Canada ULC",
    "drug_name_brand": "Xalkori",
    "drug_name_generic": "crizotinib",
    "first_publication_date": "2012-04-25",
    "publication_date": "2023-04-17",
    "status": "Active"
  },
  {
    "id": "doc:hc.xospata",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Xospata (gilteritinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Astellas Pharma Canada, Inc. Xospata (gilteritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064190.PDF. Revised January 2022. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00064190.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98500"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Astellas Pharma Canada, Inc.",
    "drug_name_brand": "Xospata",
    "drug_name_generic": "gilteritinib",
    "first_publication_date": "2019-12-23",
    "publication_date": "2022-01-04",
    "status": "Active"
  },
  {
    "id": "doc:hc.yervoy",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Yervoy (ipilimumab) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Bristol-Myers Squibb Canada. Yervoy (ipilimumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074279.PDF. Revised December 2023. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00074279.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86525"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Bristol-Myers Squibb Canada",
    "drug_name_brand": "Yervoy",
    "drug_name_generic": "ipilimumab",
    "first_publication_date": "2012-02-01",
    "publication_date": "2023-12-07",
    "status": "Active"
  },
  {
    "id": "doc:hc.zelboraf",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Zelboraf (vemurafenib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Hoffmann-La Roche Limited. Zelboraf (vemurafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00054278.PDF. Revised December 2019. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00054278.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86606"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Hoffmann-La Roche Limited",
    "drug_name_brand": "Zelboraf",
    "drug_name_generic": "vemurafenib",
    "first_publication_date": null,
    "publication_date": "2019-12-10",
    "status": "Active"
  },
  {
    "id": "doc:hc.zykadia",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Zykadia (ceritinib) [product monograph]. HC.",
    "title": null,
    "aliases": [],
    "description": "Novartis Pharmaceuticals Canada Inc. Zykadia (ceritinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00064867.PDF. Revised February 2022. Accessed June 2025.",
    "urls": [
      "https://pdf.hres.ca/dpd_pm/00064867.PDF",
      "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92108"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hc",
    "application_number": null,
    "company": "Novartis Pharmaceuticals Canada Inc.",
    "drug_name_brand": "Zykadia",
    "drug_name_generic": "ceritinib",
    "first_publication_date": "2015-03-27",
    "publication_date": "2022-02-25",
    "status": "Active"
  },
  {
    "id": "doc:fda.modeyso",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Modeyso (dordaviprone) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Chimerix, Inc. Modeyso (dordaviprone) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219876s000lbl.pdf. Revised August 2025. Accessed October 2, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219876s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219876"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 219876,
    "company": "Chimerix, Inc.",
    "drug_name_brand": "Modeyso",
    "drug_name_generic": "dordaviprone",
    "first_publication_date": "2025-08-06",
    "publication_date": "2025-08-06",
    "status": "Active"
  },
  {
    "id": "doc:fda.inluriyo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Inluriyo (imlunestrant) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Eli and Lily Company. Inluriyo (imlunestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218881s000lbl.pdf. Revised September 2025. Accessed October 2, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218881s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218881"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 218881,
    "company": "Eli and Lily Company",
    "drug_name_brand": "Inluriyo",
    "drug_name_generic": "imlunestrant",
    "first_publication_date": "2025-09-25",
    "publication_date": "2025-09-25",
    "status": "Active"
  },
  {
    "id": "doc:ema.voranigo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Voranigo (vorasidenib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Les Laboratoires Servier. Voranigo (vorasidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/voranigo-epar-product-information_en.pdf. Revised September 2025. Accessed October 2, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/voranigo-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/voranigo"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Les Laboratoires Servier",
    "drug_name_brand": "Voranigo",
    "drug_name_generic": "vorasidenib",
    "first_publication_date": "2025-09-26",
    "publication_date": "2025-09-26",
    "status": "Active"
  },
  {
    "id": "doc:ema.ziihera",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ziihera (zanidatamab) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Jazz Pharmaceuticals Ireland Limited. Ziihera (zanidatamab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ziihera-epar-product-information_en.pdf.pdf. Revised July 2025. Accessed September 8, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/ziihera-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/ziihera"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Jazz Pharmaceuticals Ireland Limited",
    "drug_name_brand": "Ziihera",
    "drug_name_generic": "zanidatamab",
    "first_publication_date": "2025-07-03",
    "publication_date": "2025-07-03",
    "status": "Active"
  },
  {
    "id": "doc:ema.itovebi",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Itovebi (inavolisib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Roche Registration GmbH. Itovebi (inavolisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/itovebi-epar-product-information_en.pdf.pdf. Revised August 2025. Accessed September 8, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/itovebi-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/itovebi"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Roche Registration GmbH",
    "drug_name_brand": "Itovebi",
    "drug_name_generic": "inavolisib",
    "first_publication_date": "2025-08-27",
    "publication_date": "2025-08-27",
    "status": "Active"
  },
  {
    "id": "doc:ema.vanflyta",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vanflyta (quizartinib) [product information]. EMA.",
    "title": null,
    "aliases": [],
    "description": "Daiichi Sankyo Europe GmbH. Vanflyta (quizartinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vanflyta-epar-product-information_en.pdf. Revised December 2024. Accessed October 20, 2025.",
    "urls": [
      "https://www.ema.europa.eu/en/documents/product-information/vanflyta-epar-product-information_en.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/vanflyta"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "ema",
    "application_number": null,
    "company": "Daiichi Sankyo Europe GmbH",
    "drug_name_brand": "Vanflyta",
    "drug_name_generic": "quizartinib",
    "first_publication_date": "2023-11-21",
    "publication_date": "2024-12-18",
    "status": "Active"
  },
  {
    "id": "doc:fda.vanflyta",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vanflyta (quizartinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Daiichi Sankyo, Inc. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216993s001lbl.pdf. Revised June 2024. Accessed October 3, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216993s001lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216993"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 216993,
    "company": "Daiichi Sankyo, Inc.",
    "drug_name_brand": "Vanflyta",
    "drug_name_generic": "quizartinib",
    "first_publication_date": "2023-07-20",
    "publication_date": "2024-06-25",
    "status": "Active"
  },
  {
    "id": "doc:fda.imbruvica",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Imbruvica (ibrutinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Pharmacyclics LLC. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205552s043,210563s019,217003s004lbl.pdf. Revised December 2024. Accessed October 3, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205552s043,210563s019,217003s004lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210563"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 210563,
    "company": "Pharmacyclics LLC",
    "drug_name_brand": "Imbruvica",
    "drug_name_generic": "ibrutinib",
    "first_publication_date": "2018-02-16",
    "publication_date": "2024-12-20",
    "status": "Active"
  },
  {
    "id": "doc:fda.komzifti",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Komzifti (ziftomenib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Kura Oncology, Inc. Komzifti (ziftomenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220305s000lbl.pdf. Revised November 2025. Accessed December 23, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220305s000lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220305"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 220305,
    "company": "Kura Oncology, Inc",
    "drug_name_brand": "Komzifti",
    "drug_name_generic": "ziftomenib",
    "first_publication_date": "2025-11-13",
    "publication_date": "2025-11-13",
    "status": "Active"
  },
  {
    "id": "doc:fda.hyrnuo",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Hyrnuo (sevabertinib) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "Bayer HealthCare Pharmaceuticals Inc. Hyrnuo (sevabertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219972s000lblCorrected.pdf. Revised November 2025. Accessed December 23, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219972s000lblCorrected.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219972"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 219972,
    "company": "Bayer HealthCare Pharmaceuticals Inc.",
    "drug_name_brand": "Hyrnuo",
    "drug_name_generic": "sevabertinib",
    "first_publication_date": "2025-11-19",
    "publication_date": "2025-11-19",
    "status": "Active"
  },
  {
    "id": "doc:fda.tevimbra",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tevimbra (tislelizumab-jsgr) [package insert]. FDA.",
    "title": null,
    "aliases": [],
    "description": "BeOne Medicines USA, Inc. Tevimbra (tislelizumab-jsgr) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf. Revised December 2025. Accessed December 26, 2025.",
    "urls": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf",
      "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761232"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "fda",
    "application_number": 761232,
    "company": "BeOne Medicines USA, Inc.",
    "drug_name_brand": "Tevimbra",
    "drug_name_generic": "tislelizumab",
    "first_publication_date": "2024-03-13",
    "publication_date": "2025-12-09",
    "status": "Active"
  },
  {
    "id": "doc:hse.00221",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Afatinib Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Afatinib Monotherapy, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 16/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/221.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/221.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-02-26",
    "status": "Active"
  },
  {
    "id": "doc:hse.00401",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Alectinib Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Alectinib Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/401.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/401.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-05-13",
    "status": "Active"
  },
  {
    "id": "doc:hse.00847",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Asciminib Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Asciminib Monotherapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 16/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/847-asciminib-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/847-asciminib-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-11-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00224",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Bosutinib Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Bosutinib Monotherapy, 2021, version number 4, NCCP National SACT Regimen, viewed 19/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/224-bosutinib-monotherapy-regimen.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/224-bosutinib-monotherapy-regimen.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-03-22",
    "status": "Active"
  },
  {
    "id": "doc:hse.00562",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Brigatinib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Brigatinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 19/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/562-brigatinib-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/562-brigatinib-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-10-22",
    "status": "Active"
  },
  {
    "id": "doc:hse.00340",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ceritinib Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Ceritinib Monotherapy, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 19/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/340-ceritinib-monotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/340-ceritinib-monotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-11-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00373",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Cobimetinib and Vemurafenib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Cobimetinib and Vemurafenib Therapy, 2020, version number 2, NCCP National SACT Regimen, NCCP, viewed 19/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/cobimetinib%20and%20vemurafenib%20therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/cobimetinib%20and%20vemurafenib%20therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-05-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00243",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Crizotinib Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Crizotinib Monotherapy, 2020, version number 6, NCCP National SACT Regimen, NCCP, viewed 19/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/243-crizotinib-monotherapy-regimen.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/243-crizotinib-monotherapy-regimen.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-01-08",
    "status": "Active"
  },
  {
    "id": "doc:hse.00237",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Dabrafenib Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Dabrafenib Monotherapy, 2021, version number 5, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/237dabrafenib.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/237dabrafenib.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-06-23",
    "status": "Active"
  },
  {
    "id": "doc:hse.00565",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Dacomitinib Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Dacomitinib Monotherapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/565-dacomitinib-monotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/565-dacomitinib-monotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-06-23",
    "status": "Active"
  },
  {
    "id": "doc:hse.00563",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Encorafenib and Binimetinib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Encorafenib and Binimetinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/563-envorafenib-and-binimetinib-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/563-envorafenib-and-binimetinib-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-06-23",
    "status": "Active"
  },
  {
    "id": "doc:hse.00570",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lorlatinib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Lorlatinib Therapy, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/570%20lorlatinib%20therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/570%20lorlatinib%20therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-09-29",
    "status": "Active"
  },
  {
    "id": "doc:hse.00682",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Midostaurin, DAUNOrubicin and Cytarabine Induction Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Midostaurin, DAUNOrubicin and Cytarabine Induction Therapy, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/682.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/682.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-12-08",
    "status": "Active"
  },
  {
    "id": "doc:hse.00720",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Neratinib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Neratinib Therapy, 2022, version number 1, NCCP National SACT Regimen, NCCP, viewed 11/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-02-09",
    "status": "Active"
  },
  {
    "id": "doc:hse.00848",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Niraparib and Abiraterone acetate (Akeega) and prednisoLONE Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Niraparib and Abiraterone acetate (Akeega) and prednisoLONE Therapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/848-niraparib-and-abiraterone-acetate-akeega-and-prednisolone-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/848-niraparib-and-abiraterone-acetate-akeega-and-prednisolone-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-11-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00746",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Olaparib (Tablet) and Bevacizumab Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Olaparib (Tablet) and Bevacizumab Therapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-09-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00588",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Olaparib (Tablet) Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Olaparib (Tablet) Monotherapy, 2025, version number 5b, NCCP National SACT Regimen, NCCP, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/588-olaparib-tablet-monotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/588-olaparib-tablet-monotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-05-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00353",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Osimertinib Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Osimertinib Monotherapy, 2024, version number 5, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-03-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00302",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "PONATinib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "PONATinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/ponatinib-therapy-302.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/ponatinib-therapy-302.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-06-21",
    "status": "Active"
  },
  {
    "id": "doc:hse.00605",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Talazoparib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Talazoparib Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/605-talazoparib-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/605-talazoparib-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-09-06",
    "status": "Active"
  },
  {
    "id": "doc:hse.00415",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trametinib and Dabrafenib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Trametinib and Dabrafenib Therapy, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed on 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-11-11",
    "status": "Active"
  },
  {
    "id": "doc:hse.00102",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vemurafenib Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Vemurafenib Monotherapy, 2020, version number 5, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/102-vemurafenib-monotherapy-regimen.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/102-vemurafenib-monotherapy-regimen.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-01-08",
    "status": "Active"
  },
  {
    "id": "doc:hse.00400",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Venetoclax Monotherapy 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Venetoclax Monotherapy 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-03-03",
    "status": "Active"
  },
  {
    "id": "doc:hse.00708",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Zanubrutinib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Zanubrutinib Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/708-zanubrutinib-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/708-zanubrutinib-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-09-12",
    "status": "Active"
  },
  {
    "id": "doc:hse.00840",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Acalabrutinib (Tablets) Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Acalabrutinib (Tablets) Monotherapy, 2023, version number 1a, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/840-acalabrutinib-tablets-monotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/840-acalabrutinib-tablets-monotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-12-13",
    "status": "Active"
  },
  {
    "id": "doc:hse.00296",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ibrutinib Therapy CLL / Waldenstroms Macroglobulinaemia. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Ibrutinib Therapy CLL / Waldenstroms Macroglobulinaemia, 2022, version number 5, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-11-28",
    "status": "Active"
  },
  {
    "id": "doc:hse.00551",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nivolumab 3mg/kg with Ipilimumab 1mg/kg Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Nivolumab 3mg/kg with Ipilimumab 1mg/kg Therapy, 2023, version number 6, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/551-nivolumab-3mg-ipilimumab-1mg-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/551-nivolumab-3mg-ipilimumab-1mg-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-06-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00455",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab 200mg Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab 200mg Monotherapy, 2023, version number 13, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-200mg-monotherapy-455.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-200mg-monotherapy-455.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-04-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.P00760",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Larotrectinib Monotherapy - Paediatric. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Larotrectinib Monotherapy - Paediatric, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 01/02/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/760%20larotrectinib-monotherapy-paediatric.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/760%20larotrectinib-monotherapy-paediatric.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-04-28",
    "status": "Active"
  },
  {
    "id": "doc:hse.00758",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Larotrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Larotrectinib Monotherapy - Adult, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 01/02/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/758-larotrectinib-monotherapy-adult.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/758-larotrectinib-monotherapy-adult.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-04-28",
    "status": "Active"
  },
  {
    "id": "doc:hse.00219",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Erlotinib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Erlotinib Therapy, 2021, version number 5, NCCP National SACT Regimen, NCCP, viewed 22/02/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/219.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/219.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-03-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00206",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trastuzumab Emtansine (Kadcyla) - 21 days. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Trastuzumab Emtansine (Kadcyla) - 21 days, 2017, version number 2, NCCP National SACT Regimen, NCCP, viewed 01/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/trastuzumab-emtansine-kadcyla%C2%AE-21-days.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/trastuzumab-emtansine-kadcyla%C2%AE-21-days.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2017-09-20",
    "status": "Active"
  },
  {
    "id": "doc:hse.00414",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Palbociclib Therapy - 28 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Palbociclib Therapy - 28 day, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 01/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-10-23",
    "status": "Active"
  },
  {
    "id": "doc:hse.00525",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ribociclib Therapy - 28 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Ribociclib Therapy - 28 day, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 03/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-08-19",
    "status": "Active"
  },
  {
    "id": "doc:hse.00537",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Inotuzumab Ozogamicin Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Inotuzumab Ozogamicin Monotherapy, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 03/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/537-inotuzumab-ozogamicin-monotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/537-inotuzumab-ozogamicin-monotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-11-19",
    "status": "Active"
  },
  {
    "id": "doc:hse.P0567",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Blinatumomab Paediatric Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Blinatumomab Paediatric Therapy, 2019, version number 1, NCCP National SACT Regimen, NCCP, viewed 03/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/p567-blinatumomab-paediatric-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/p567-blinatumomab-paediatric-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2019-07-16",
    "status": "Active"
  },
  {
    "id": "doc:hse.00530",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP). NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP), 2019, version number 2, NCCP National SACT Regimen, NCCP, viewed 16/10/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/530.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/530.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-08-24",
    "status": "Active"
  },
  {
    "id": "doc:hse.00350",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pertuzumab and Trastuzumab and Chemotherapy Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pertuzumab and Trastuzumab and Chemotherapy Therapy - 21 day cycle, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00612",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Gemtuzumab ozogamicin DAUNOrubicin and cytarabine Therapy (AML induction). NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Gemtuzumab ozogamicin DAUNOrubicin and cytarabine Therapy (AML induction), 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/612-gemtuzumab-ozogamicin-therpay.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/612-gemtuzumab-ozogamicin-therpay.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-07-29",
    "status": "Active"
  },
  {
    "id": "doc:hse.00568",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/568.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/568.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-07-04",
    "status": "Active"
  },
  {
    "id": "doc:hse.00569",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab, PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab, PEMEtrexed and CISplatin Therapy, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/569.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/569.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-12-19",
    "status": "Active"
  },
  {
    "id": "doc:hse.00576",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Durvalumab Monotherapy 10mg/kg - 14 Day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Durvalumab Monotherapy 10mg/kg - 14 Day, 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/576.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/576.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-09-04",
    "status": "Active"
  },
  {
    "id": "doc:hse.00544",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Atezolizumab Monotherapy, 2024, version number 13, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-06-14",
    "status": "Active"
  },
  {
    "id": "doc:hse.00659",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trastuzumab Emtansine (Kadcyla) Early Breast Cancer Therapy - 21 days. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Trastuzumab Emtansine (Kadcyla) Early Breast Cancer Therapy - 21 days, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/659-trastuzumab-emtansine-kadcyla-early-breast-cancer-therapy-21-days.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/659-trastuzumab-emtansine-kadcyla-early-breast-cancer-therapy-21-days.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-02-23",
    "status": "Active"
  },
  {
    "id": "doc:hse.00705",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy, 2023, version number 2a, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/705-pembrolizumab-carboplatin-and-5-fu-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/705-pembrolizumab-carboplatin-and-5-fu-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-11-21",
    "status": "Active"
  },
  {
    "id": "doc:hse.00706",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab, Cisplatin and 5-Fluorouracil Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab, Cisplatin and 5-Fluorouracil Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/706-pembrolizumab-cisplatin-and-5-fu-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/706-pembrolizumab-cisplatin-and-5-fu-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-04-26",
    "status": "Active"
  },
  {
    "id": "doc:hse.00712",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/712.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/712.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-12-14",
    "status": "Active"
  },
  {
    "id": "doc:hse.00713",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy, 2025, version number 3, NCCP National SACT Regimen, NCCP, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/713.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/713.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-05-14",
    "status": "Active"
  },
  {
    "id": "doc:hse.00714",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy, 2025, version number 3, NCCP National SACT Regimen, NCCP, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/714.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/714.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-05-13",
    "status": "Active"
  },
  {
    "id": "doc:hse.00688",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Atezolizumab and nab-PACLitaxel Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Atezolizumab and nab-PACLitaxel Therapy, 2022, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/688.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/688.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-12-16",
    "status": "Active"
  },
  {
    "id": "doc:hse.00590",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Blinatumomab Therapy (ALL with MRD >= 0.1%). NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Blinatumomab Therapy (ALL with MRD >= 0.1%), 2022, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/590-blinatumomab-mrd.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/590-blinatumomab-mrd.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-10-04",
    "status": "Active"
  },
  {
    "id": "doc:hse.P00707",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy, 2022, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/paediatric/707-blinatumomab-rall-consolidation-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/paediatric/707-blinatumomab-rall-consolidation-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-05-06",
    "status": "Active"
  },
  {
    "id": "doc:hse.00790",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pertuzumab and Trastuzumab (Phesgo), PACLitaxel and CARBOplatin Therapy (TRAIN-2). NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pertuzumab and Trastuzumab (Phesgo), PACLitaxel and CARBOplatin Therapy (TRAIN-2), 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/790-pertuzumab-trastuzumab-phesgo-paclitaxel-and-carboplatin-therapy-train-2-.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/790-pertuzumab-trastuzumab-phesgo-paclitaxel-and-carboplatin-therapy-train-2-.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00234",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Brentuximab vedotin Monotherapy, 2022, version number 5, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-12-20",
    "status": "Active"
  },
  {
    "id": "doc:hse.00528",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Brentuximab vedotin and ICE Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Brentuximab vedotin and ICE Therapy, 2020, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/528.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/528.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-11-12",
    "status": "Active"
  },
  {
    "id": "doc:hse.00739",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy, 2024, version number 1c, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/739-pembrolizumab-200mg-cisplatin-80mg-m2-and-5-fluorouracil-infusional-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/739-pembrolizumab-200mg-cisplatin-80mg-m2-and-5-fluorouracil-infusional-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-01-26",
    "status": "Active"
  },
  {
    "id": "doc:hse.00832",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/832-nivolumab-cisplatin.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/832-nivolumab-cisplatin.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-01-08",
    "status": "Active"
  },
  {
    "id": "doc:hse.00593",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Atezolizumab 1680mg Monotherapy - 28 Day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Atezolizumab 1680mg Monotherapy - 28 Day, 2024, version number 10a, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-03-26",
    "status": "Active"
  },
  {
    "id": "doc:hse.00839",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab and FOLFOX-6 Modified Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/839-pembrolizumab-and-folfox-6-modified-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/839-pembrolizumab-and-folfox-6-modified-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-01-26",
    "status": "Active"
  },
  {
    "id": "doc:hse.00538",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Blinatumomab Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Blinatumomab Therapy, 2022, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/538-blinatumomab-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/538-blinatumomab-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-10-04",
    "status": "Active"
  },
  {
    "id": "doc:hse.00797",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pertuzumab/Trastuzumab (Phesgo) and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pertuzumab/Trastuzumab (Phesgo) and Weekly PACLitaxel Therapy - 21 day cycle, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/797-pertuzumab-trastuzumab-phesgo-and-weekly-paclitaxel-therapy-21-day-cycle.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/797-pertuzumab-trastuzumab-phesgo-and-weekly-paclitaxel-therapy-21-day-cycle.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00507",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pertuzumab,Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pertuzumab,Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle, 2023, version number 5, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/507.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/507.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00796",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pertuzumab/Trastuzumab (Phesgo) and DOCEtaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pertuzumab/Trastuzumab (Phesgo) and DOCEtaxel Therapy - 21 day cycle, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/796-pertuzumab-and-trastuzumab-phesgo-and-docetaxel-therapy-21-day-cycle.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/796-pertuzumab-and-trastuzumab-phesgo-and-docetaxel-therapy-21-day-cycle.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00204",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pertuzumab,Trastuzumab and DOCEtaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pertuzumab,Trastuzumab and DOCEtaxel Therapy - 21 day cycle, 2023, version number 10, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/204-pertuzumab-and-trastuzumab-and-docetaxel-therapy-21-day-cycle.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/204-pertuzumab-and-trastuzumab-and-docetaxel-therapy-21-day-cycle.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00798",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pertuzumab/Trastuzumab (Phesgo) and Vinorelbine. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pertuzumab/Trastuzumab (Phesgo) and Vinorelbine, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/798-pertuzumab-trastuzumab-phesgo-and-vinorelbine-i-.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/798-pertuzumab-trastuzumab-phesgo-and-vinorelbine-i-.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00526",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pertuzumab, Trastuzumab, and Vinorelbine. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pertuzumab, Trastuzumab, and Vinorelbine, 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/526-pertuzumab-trastuzumab-and-vinorelbine.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/526-pertuzumab-trastuzumab-and-vinorelbine.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00785",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/785-pertuzumab-and-trastuzumab-phesgo-maintenance-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/785-pertuzumab-and-trastuzumab-phesgo-maintenance-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00722",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/722-docetaxel-carboplatin-trastuzumab-and-pertuzumab-tchp-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/722-docetaxel-carboplatin-trastuzumab-and-pertuzumab-tchp-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00849",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nivolumab 360mg and Chemotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Nivolumab 360mg and Chemotherapy, 2024, version number 1, NCCP National SACT Regimen, NCCP, viewed 19/06/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/849-nivolumab-360mg-and-chemotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/849-nivolumab-360mg-and-chemotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-04-27",
    "status": "Active"
  },
  {
    "id": "doc:hse.00858",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab 200mg, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab 200mg, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy, 2024, version number 1, NCCP National SACT Regimen, NCCP, viewed 19/06/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/858-pembrolizumab-200mg-weekly-carboplatin-auc-1-5-and-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/858-pembrolizumab-200mg-weekly-carboplatin-auc-1-5-and-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-06-04",
    "status": "Active"
  },
  {
    "id": "doc:hse.00200",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trastuzumab (IV) Monotherapy - 21 days. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Trastuzumab (IV) Monotherapy - 21 days, 2022, version number 7, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-04-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00212",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Bevacizumab 10mg/kg - 14 days. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Bevacizumab 10mg/kg - 14 days, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/212.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/212.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-04-28",
    "status": "Active"
  },
  {
    "id": "doc:hse.00215",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Bevacizumab 15mg/kg Therapy - 21 days. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Bevacizumab 15mg/kg Therapy - 21 days, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/215.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/215.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-04-28",
    "status": "Active"
  },
  {
    "id": "doc:hse.00217",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Lapatinib and Capecitabine Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Lapatinib and Capecitabine Therapy, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/217.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/217.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-02-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00253",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tamoxifen Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Tamoxifen Monotherapy, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-11-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00254",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Anastrozole Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Anastrozole Monotherapy, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-11-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00272",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-09-09",
    "status": "Active"
  },
  {
    "id": "doc:hse.00285",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trastuzumab Subcutaneous 21 days - Early Breast Cancer. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Trastuzumab Subcutaneous 21 days - Early Breast Cancer, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-09-09",
    "status": "Active"
  },
  {
    "id": "doc:hse.00361",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Fulvestrant Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Fulvestrant Therapy, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/361.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/361.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-12-09",
    "status": "Active"
  },
  {
    "id": "doc:hse.00371",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Letrozole Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Letrozole Monotherapy, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-12-09",
    "status": "Active"
  },
  {
    "id": "doc:hse.00376",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Exemestane Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Exemestane Monotherapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-01-06",
    "status": "Active"
  },
  {
    "id": "doc:hse.00430",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days, 2023, version number 5, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/430-gemcitabine-and-carboplatin-auc2-therapy-21-days.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/430-gemcitabine-and-carboplatin-auc2-therapy-21-days.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-09-22",
    "status": "Active"
  },
  {
    "id": "doc:hse.00619",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Abemaciclib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Abemaciclib Therapy, 2024, version number 1, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-05-31",
    "status": "Active"
  },
  {
    "id": "doc:hse.00726",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pertuzumab and Trastuzumab Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pertuzumab and Trastuzumab Therapy, 2024, version number 3a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/726-pertuzumab-trastuzumab-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/726-pertuzumab-trastuzumab-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-05-29",
    "status": "Active"
  },
  {
    "id": "doc:hse.00731",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "DOCEtaxel, CARBOplatin, Trastuzumab (S/C) and Pertuzumab (TCH(S/C)P) Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "DOCEtaxel, CARBOplatin, Trastuzumab (S/C) and Pertuzumab (TCH(S/C)P) Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/731-docetaxel-carboplatin-trastuzumab-s-c-and-pertuzumab-tch-s-c-p-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/731-docetaxel-carboplatin-trastuzumab-s-c-and-pertuzumab-tch-s-c-p-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00775",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2). NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2), 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/775-pertuzumab-trastuzumab-paclitaxel-and-carboplatin-therapy-train-2-.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/775-pertuzumab-trastuzumab-paclitaxel-and-carboplatin-therapy-train-2-.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-08-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00789",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo)(TCHP) Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo)(TCHP) Therapy, 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/789-docetaxel-carboplatin-and-pertuzumab-trastuzumab-phesgo-tchp-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/789-docetaxel-carboplatin-and-pertuzumab-trastuzumab-phesgo-tchp-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-06-07",
    "status": "Active"
  },
  {
    "id": "doc:hse.00857",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab 200mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab 200mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy, 2024, version number 1, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/857-pembrolizumab-200mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/857-pembrolizumab-200mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-06-04",
    "status": "Active"
  },
  {
    "id": "doc:hse.00225",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Panitumumab 6mg/kg Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Panitumumab 6mg/kg Therapy, 2020, version number 5, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/225.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/225.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-11-10",
    "status": "Active"
  },
  {
    "id": "doc:hse.00328",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Cetuximab (7 days) and FOLFIRI (14 days) Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Cetuximab (7 days) and FOLFIRI (14 days) Therapy, 2023, version number 6a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/328.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/328.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-11-23",
    "status": "Active"
  },
  {
    "id": "doc:hse.00816",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy, 2023, version number 1a, NCCP National SACT Regimen, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/816-nivolumab-cisplatin.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/816-nivolumab-cisplatin.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-11-21",
    "status": "Active"
  },
  {
    "id": "doc:hse.00844",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nivolumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Nivolumab and FOLFOX-6 Modified Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/844-nivolumab-and-folfox-6-modified-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/844-nivolumab-and-folfox-6-modified-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-02-20",
    "status": "Active"
  },
  {
    "id": "doc:hse.00558",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab 400mg Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab 400mg Monotherapy, 2023, version number 10, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-400mg-monotherapy-558.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-400mg-monotherapy-558.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-04-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00811",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/811-pembrolizumab-paclitaxel-carboplatin-auc.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/811-pembrolizumab-paclitaxel-carboplatin-auc.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-04-17",
    "status": "Active"
  },
  {
    "id": "doc:hse.00817",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/817-pembrolizumab-paclitaxel-carboplatin-auc-5-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/817-pembrolizumab-paclitaxel-carboplatin-auc-5-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-04-17",
    "status": "Active"
  },
  {
    "id": "doc:hse.00661",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Midostaurin Maintenance Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Midostaurin Maintenance Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/661.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/661.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-12-08",
    "status": "Active"
  },
  {
    "id": "doc:hse.00683",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/683-midostaurin-intermediate-dose-cytarabine-consolidation-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/683-midostaurin-intermediate-dose-cytarabine-consolidation-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-12-08",
    "status": "Active"
  },
  {
    "id": "doc:hse.00281",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy - 21 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy - 21 day, 2024, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/281-gemcitabine-1250mg-m2-and-cisplatin-75mg-m2-therapy-21days.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/281-gemcitabine-1250mg-m2-and-cisplatin-75mg-m2-therapy-21days.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-05-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00304",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "CARBOplatin (AUC 6) and PACLitaxel 200mg/m2 Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "CARBOplatin (AUC 6) and PACLitaxel 200mg/m2 Therapy, 2024, version number 7, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/304-carboplatin-auc6-and-paclitaxel-200mg-m2-therapy-.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/304-carboplatin-auc6-and-paclitaxel-200mg-m2-therapy-.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-05-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00310",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy - 21 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy - 21 day, 2024, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/310.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/310.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-05-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00317",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "PEMEtrexed and CISplatin Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "PEMEtrexed and CISplatin Therapy, 2024, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/317-pemetrexed-and-cisplatin-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/317-pemetrexed-and-cisplatin-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-05-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00318",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "PEMEtrexed and CARBOplatin Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "PEMEtrexed and CARBOplatin Therapy, 2024, version number 5, NCCP National SACT Regimen, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/318-pemetrexed-and-carboplatin-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/318-pemetrexed-and-carboplatin-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-05-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00592",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Atezolizumab 840mg Monotherapy - 14 Day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Atezolizumab 840mg Monotherapy - 14 Day, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-02-19",
    "status": "Active"
  },
  {
    "id": "doc:hse.00655",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Durvalumab Monotherapy 1500 mg - 28 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Durvalumab Monotherapy 1500 mg - 28 day, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/655-durvalumab-1500mg-monotherapy-28-day.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/655-durvalumab-1500mg-monotherapy-28-day.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-09-04",
    "status": "Active"
  },
  {
    "id": "doc:hse.00307",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy - 21 days. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy - 21 days, 2024, version number 5a, NCCP National SACT Regimen, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/307.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/307.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-09-04",
    "status": "Active"
  },
  {
    "id": "doc:hse.00397",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "(R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "(R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy, 2022, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/397.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/397.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-09-21",
    "status": "Active"
  },
  {
    "id": "doc:hse.00409",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP Therapy - 14 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP Therapy - 14 day, 2024, version number 5a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/409.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/409.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-07-05",
    "status": "Active"
  },
  {
    "id": "doc:hse.00436",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "(R*)- miniCHOP Therapy - 21 days. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "(R*)- miniCHOP Therapy - 21 days, 2023, version number 4, NCCP National SACT Regimen, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/436-r-minichop-therapy-%E2%80%93-21-days.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/436-r-minichop-therapy-%E2%80%93-21-days.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-11-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00506",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/506.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/506.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-08-19",
    "status": "Active"
  },
  {
    "id": "doc:hse.00510",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "R-CEOP Therapy - 21 days. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "R-CEOP Therapy - 21 days, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/510-r-ceop-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/510-r-ceop-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-02-03",
    "status": "Active"
  },
  {
    "id": "doc:hse.00389",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Idelalisib and riTUXimab Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Idelalisib and riTUXimab Therapy, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/idelalisib-and-rituximab-v2-389.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/idelalisib-and-rituximab-v2-389.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2019-02-11",
    "status": "Active"
  },
  {
    "id": "doc:hse.00529",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Brentuximab vedotin and Bendamustine Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Brentuximab vedotin and Bendamustine Therapy, 2019, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/529-brentuximab-vedotin-and-bendamustine-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/529-brentuximab-vedotin-and-bendamustine-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2019-10-18",
    "status": "Active"
  },
  {
    "id": "doc:hse.00542",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "riTUXimab 375 mg/m2 Combination Therapy-21 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "riTUXimab 375 mg/m2 Combination Therapy-21 day, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/542-rituximab-375-mg-m2-combination-therapy-21-day.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/542-rituximab-375-mg-m2-combination-therapy-21-day.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-03-31",
    "status": "Active"
  },
  {
    "id": "doc:hse.00543",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/543-rituximab-375-mg-m2-maintenance-therapy-56-day.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/543-rituximab-375-mg-m2-maintenance-therapy-56-day.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-03-31",
    "status": "Active"
  },
  {
    "id": "doc:hse.00599",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "riTUXimab (S/C 1400mg) Maintenance Therapy-84 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "riTUXimab (S/C 1400mg) Maintenance Therapy-84 day, 2022, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/599.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/599.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-10-12",
    "status": "Active"
  },
  {
    "id": "doc:hse.00600",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "riTUXimab (S/C 1400mg) Maintenance Therapy-56 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "riTUXimab (S/C 1400mg) Maintenance Therapy-56 day, 2022, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/600.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/600.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-10-12",
    "status": "Active"
  },
  {
    "id": "doc:hse.00672",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/dose-adjusted-rituximab-s-c-etoposide-prednisolone-doxorubicin-cyclophosphamide-and-vincristine-da-r-s-c-epoch-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/dose-adjusted-rituximab-s-c-etoposide-prednisolone-doxorubicin-cyclophosphamide-and-vincristine-da-r-s-c-epoch-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-11-06",
    "status": "Active"
  },
  {
    "id": "doc:hse.00293",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days, 2022, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/r-cvp-v3-293.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/r-cvp-v3-293.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2022-06-27",
    "status": "Active"
  },
  {
    "id": "doc:hse.00540",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "RiTUXimab 375 mg/m2 Maintenance Therapy-84 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "RiTUXimab 375 mg/m2 Maintenance Therapy-84 day, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/rituximab-375-mg-m2-maintenance-therapy-84-day.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/rituximab-375-mg-m2-maintenance-therapy-84-day.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2021-03-31",
    "status": "Active"
  },
  {
    "id": "doc:hse.00335",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Imatinib Therapy - GIST. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Imatinib Therapy - GIST, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/335-imatinib-therapy-gist.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/335-imatinib-therapy-gist.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2020-07-15",
    "status": "Active"
  },
  {
    "id": "doc:hse.00823",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Tepotinib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Tepotinib Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 19/08/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/823-tepotinib-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/823-tepotinib-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-08-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00776",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trastuzumab Deruxtecan (Enhertu) Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Trastuzumab Deruxtecan (Enhertu) Therapy, 2025, version number 3b, NCCP National SACT Regimen, NCCP, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/776-trastuzumab-deruxtecan-enhertu-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/776-trastuzumab-deruxtecan-enhertu-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-06-25",
    "status": "Active"
  },
  {
    "id": "doc:hse.00860",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 19/08/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/860-pembrolizumab-400mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-and-cyclophosphamide-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/860-pembrolizumab-400mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-and-cyclophosphamide-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-06-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00861",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 19/08/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/861-pembrolizumab-400mg-weekly-carboplatin-auc-1-5-and-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-and-cyclophosphamide-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/861-pembrolizumab-400mg-weekly-carboplatin-auc-1-5-and-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-and-cyclophosphamide-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-07-18",
    "status": "Active"
  },
  {
    "id": "doc:hse.00242",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Vandetanib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Vandetanib Therapy, 2023, version number 5, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/242vandetanibmonotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/242vandetanibmonotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-02-07",
    "status": "Active"
  },
  {
    "id": "doc:hse.00356",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Trentinoin (ATRA) and Arsenic Trioxide (ATO) Induction Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Trentinoin (ATRA) and Arsenic Trioxide (ATO) Induction Therapy, 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/356-tretinoin-atra-with-arsenic-trioxide-ato-induction-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/356-tretinoin-atra-with-arsenic-trioxide-ato-induction-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2023-09-20",
    "status": "Active"
  },
  {
    "id": "doc:hse.00794",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Sacituzumab Govitecan Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Sacituzumab Govitecan Therapy, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/794-sacituzumab-govitecan-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/794-sacituzumab-govitecan-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-08-29",
    "status": "Active"
  },
  {
    "id": "doc:hse.00702",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Entrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Entrectinib Monotherapy - Adult, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 16/10/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2024-10-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00885",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Erdafitinib Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Erdafitinib Monotherapy, 2024, version number 1a, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/885-erdafitinib-monotherapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/885-erdafitinib-monotherapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-02-25",
    "status": "Active"
  },
  {
    "id": "doc:hse.00684",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Gilteritinib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Gilteritinib Therapy, 2025, version number 1, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/684-gilteritinib-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/684-gilteritinib-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-10-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00901",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ivosidenib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Ivosidenib Therapy, 2025, version number 1, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/901-ivosidenib-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/901-ivosidenib-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-09-25",
    "status": "Active"
  },
  {
    "id": "doc:hse.00483",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nivolumab Monotherapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Nivolumab Monotherapy, 2025, version number 11b, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/483-nivolumab-240mg-monotherapy-14-day.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/483-nivolumab-240mg-monotherapy-14-day.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-05-08",
    "status": "Active"
  },
  {
    "id": "doc:hse.00900",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Nivolumab 240 mg and Ipilimumab 1mg/kg Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Nivolumab 240 mg and Ipilimumab 1mg/kg Therapy, 2025, version number 1a, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/900-nivolumab-240mg-and-ipilimumab-1mg-kg-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/900-nivolumab-240mg-and-ipilimumab-1mg-kg-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-10-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00889",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Pemigatinib Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Pemigatinib Therapy, 2025, version number 1a, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/889-pemigatinib-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/oral-anti-cancer-medicines/889-pemigatinib-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-08-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00886",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Quizartinib, DAUNOrubicin and Cytarabine Induction Therapy. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Quizartinib, DAUNOrubicin and Cytarabine Induction Therapy, 2025, version number 1, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/886-quizartinib-daunorubicin-and-cytarabine-induction-therapy.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/886-quizartinib-daunorubicin-and-cytarabine-induction-therapy.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-02-01",
    "status": "Active"
  },
  {
    "id": "doc:hse.00892",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Ribociclib Therapy (Adjuvant) - 28 day. NCCP National SACT Regimen. HSE.",
    "title": null,
    "aliases": [],
    "description": "Ribociclib Therapy (Adjuvant) - 28 day, 2025, version number 1b, viewed 01/10/2025, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/892-ribociclib-therapy-adjuvant-28-day.pdf",
    "urls": [
      "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/892-ribociclib-therapy-adjuvant-28-day.pdf"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hse",
    "application_number": null,
    "company": "",
    "drug_name_brand": null,
    "drug_name_generic": null,
    "first_publication_date": null,
    "publication_date": "2025-09-25",
    "status": "Active"
  },
  {
    "id": "doc:hpra.arimidex",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Arimidex (anastrozole) [summary of product characteristics]. HPRA.",
    "title": null,
    "aliases": [],
    "description": "Laboratoires Juvise Pharmaceuticals. Arimidex 1mg Film-coated Tablets (Anastrozole) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf. Revised June 2021. Accessed May 25, 2025.",
    "urls": [
      "https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf",
      "https://www.hpra.ie/find-a-medicine/for-human-use/authorised-medicines/details/23881"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hpra",
    "application_number": null,
    "company": "Laboratoires Juvise Pharmaceuticals",
    "drug_name_brand": "Arimdex",
    "drug_name_generic": "anastrozole",
    "first_publication_date": null,
    "publication_date": "2021-06-09",
    "status": "Active"
  },
  {
    "id": "doc:hpra.aromasin",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Aromasin (exemestane) [summary of product characteristics]. HPRA.",
    "title": null,
    "aliases": [],
    "description": "Pfizer Healthcare Ireland. Aromasin 25 mg coated tablets (Exemestane) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/23117/Licence_PA0822-111-001_09012025155108.pdf. Revised January 2025. Accessed May 25, 2025.",
    "urls": [
      "https://assets.hpra.ie/products/Human/23117/Licence_PA0822-111-001_09012025155108.pdf",
      "https://www.hpra.ie/find-a-medicine/for-human-use/authorised-medicines/details/23117"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hpra",
    "application_number": null,
    "company": "Pfizer Healthcare Ireland",
    "drug_name_brand": "Aromasin",
    "drug_name_generic": "exemestane",
    "first_publication_date": null,
    "publication_date": "2022-06-10",
    "status": "Active"
  },
  {
    "id": "doc:hpra.femara",
    "type": "Document",
    "documentType": "Regulatory approval",
    "name": "Femara (letrozole) [summary of product characteristics]. HPRA.",
    "title": null,
    "aliases": [],
    "description": "Novartis Ireland Limited. Femara 2.5 mg film-coated tablets (Letrozole) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf. Revised August 2024. Accessed May 25, 2025.",
    "urls": [
      "https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf",
      "https://www.hpra.ie/find-a-medicine/for-human-use/authorised-medicines/details/22619"
    ],
    "doi": null,
    "pmid": null,
    "agent_id": "hpra",
    "application_number": null,
    "company": "Novartis Ireland Limited",
    "drug_name_brand": "Femara",
    "drug_name_generic": "letrozole",
    "first_publication_date": null,
    "publication_date": "2024-08-30",
    "status": "Active"
  }
]
